10-K
false--09-300001674862FYhttp://fasb.org/us-gaap/2023#AccountingStandardsUpdate201613Memberhttp://fasb.org/us-gaap/2023#IncomeLossFromDiscontinuedOperationsNetOfTaxhttp://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2023#AccountsReceivableNetCurrenthttp://fasb.org/us-gaap/2023#AccountsReceivableNetCurrenthttp://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2023#CostOfRevenuehttp://fasb.org/us-gaap/2023#CostOfRevenuehttp://fasb.org/us-gaap/2023#CostOfRevenuehttp://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrenthttp://investor.ashland.com/20230930#OtherDefinedBenefitPlanNetPeriodicBenefitIncomeExpensehttp://investor.ashland.com/20230930#OtherDefinedBenefitPlanNetPeriodicBenefitIncomeExpensehttp://investor.ashland.com/20230930#OtherDefinedBenefitPlanNetPeriodicBenefitIncomeExpensehttp://investor.ashland.com/20230930#OtherDefinedBenefitPlanNetPeriodicBenefitIncomeExpensehttp://investor.ashland.com/20230930#OtherDefinedBenefitPlanNetPeriodicBenefitIncomeExpensehttp://investor.ashland.com/20230930#OtherDefinedBenefitPlanNetPeriodicBenefitIncomeExpensehttp://investor.ashland.com/20230930#OtherDefinedBenefitPlanNetPeriodicBenefitIncomeExpensehttp://investor.ashland.com/20230930#OtherDefinedBenefitPlanNetPeriodicBenefitIncomeExpensehttp://investor.ashland.com/20230930#OtherDefinedBenefitPlanNetPeriodicBenefitIncomeExpensehttp://investor.ashland.com/20230930#OtherDefinedBenefitPlanNetPeriodicBenefitIncomeExpensehttp://investor.ashland.com/20230930#OtherDefinedBenefitPlanNetPeriodicBenefitIncomeExpensehttp://investor.ashland.com/20230930#OtherDefinedBenefitPlanNetPeriodicBenefitIncomeExpensehttp://investor.ashland.com/20230930#OtherDefinedBenefitPlanNetPeriodicBenefitIncomeExpensehttp://investor.ashland.com/20230930#OtherDefinedBenefitPlanNetPeriodicBenefitIncomeExpensehttp://investor.ashland.com/20230930#OtherDefinedBenefitPlanNetPeriodicBenefitIncomeExpensehttp://investor.ashland.com/20230930#OtherDefinedBenefitPlanNetPeriodicBenefitIncomeExpensehttp://investor.ashland.com/20230930#OtherDefinedBenefitPlanNetPeriodicBenefitIncomeExpensehttp://investor.ashland.com/20230930#OtherDefinedBenefitPlanNetPeriodicBenefitIncomeExpensehttp://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2023#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2023#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2023#SellingGeneralAndAdministrativeExpense0.3850.3850.3850.3850.3350.3350.3350.3350.3350.3350.3000.3000.3000.3000.3000.3000.2750.2750.2750.2750.2750.2750.250.250.250.25P1YP1YOne year1.5http://fasb.org/us-gaap/2023#OperatingIncomeLoss0001674862ash:LifeSciencesMembersrt:AsiaPacificMember2022-10-012023-09-3000016748622019-01-012019-03-310001674862ash:IntermediatesMembersrt:EuropeMember2022-10-012023-09-300001674862us-gaap:PerformanceSharesMember2022-10-012023-09-300001674862us-gaap:AssetBackedSecuritiesMember2022-09-300001674862ash:SpecialtyIngredientsMemberash:SpecialtyIngredientsFacilityMember2020-10-012021-09-300001674862us-gaap:FairValueInputsLevel1Memberash:InsuranceContractsMember2022-09-300001674862ash:IntermediatesAndSolventsMember2022-10-012023-09-300001674862us-gaap:BuildingMembersrt:MinimumMember2023-09-300001674862ash:ListedRealAssetsMember2022-09-300001674862us-gaap:PensionPlansDefinedBenefitMemberus-gaap:SegmentContinuingOperationsMember2023-09-300001674862srt:NorthAmericaMemberash:IntermediatesMember2022-10-012023-09-300001674862ash:AshlandGlobalHoldingsIncMember2020-09-3000016748622023-03-310001674862us-gaap:FairValueInputsLevel2Memberash:ListedRealAssetsMember2022-09-300001674862us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001674862us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2022-09-300001674862ash:PersonalCareMember2021-10-012022-09-300001674862us-gaap:OperatingSegmentsMemberash:PersonalCareAndHouseholdMember2020-10-012021-09-300001674862ash:PersonalCareMember2022-09-300001674862ash:CashSettledNonvestedStockAwardsMember2023-09-3000016748622022-07-012022-09-300001674862ash:PersonalCareMembersrt:AsiaPacificMember2022-10-012023-09-300001674862us-gaap:USGovernmentDebtSecuritiesMember2022-09-300001674862us-gaap:OperatingSegmentsMemberash:IntermediatesAndSolventsMember2021-10-012022-09-300001674862us-gaap:OtherLiabilitiesMemberus-gaap:ForeignExchangeContractMember2022-09-300001674862us-gaap:DebtSecuritiesMember2022-09-3000016748622019-10-012019-12-310001674862ash:TwoThousandTwentyThreeStockRepurchaseProgramMember2023-09-300001674862ash:TwoThousandTwentyTwoSockRepurchaseProgramMember2023-03-012023-03-310001674862ash:RestrictedSecuritiesMember2023-09-300001674862srt:MinimumMemberus-gaap:EquitySecuritiesMember2023-09-300001674862us-gaap:EquityFundsMember2023-09-300001674862ash:TwoThousandEighteenAssetBackedSecuritiesMember2023-09-300001674862ash:UnsecuredRevolvingCreditFacilityMemberash:TwoThousandTwentyTwoCreditAgreementMember2022-07-310001674862us-gaap:CustomerRelationshipsMember2022-09-300001674862us-gaap:CommonStockMember2021-09-300001674862ash:TwoThousandTwentyCreditAgreementMember2021-10-012022-09-300001674862srt:MaximumMemberash:USAccountsReceivableSalesProgramMember2022-09-300001674862ash:ExercisePriceRange1Member2022-10-012023-09-3000016748622022-09-300001674862us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:SegmentContinuingOperationsMember2021-10-012022-09-300001674862us-gaap:FairValueInputsLevel1Memberus-gaap:CorporateDebtSecuritiesMember2022-09-3000016748622020-07-012020-09-300001674862us-gaap:EquitySecuritiesMember2023-09-300001674862us-gaap:AssetBackedSecuritiesMember2023-09-300001674862us-gaap:OtherLiabilitiesMemberus-gaap:ForeignExchangeContractMember2023-09-300001674862us-gaap:FairValueInputsLevel3Memberus-gaap:CorporateDebtSecuritiesMember2022-09-300001674862srt:MinimumMemberash:CreditAgreementMemberash:AlternateBaseRateMember2023-09-300001674862us-gaap:StockCompensationPlanMember2021-09-300001674862us-gaap:RetainedEarningsMember2022-09-300001674862ash:IntermediatesMembersrt:EuropeMember2021-10-012022-09-300001674862us-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2022-09-300001674862us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberash:CreditAgreementMember2023-09-300001674862srt:MinimumMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberash:CreditAgreementMember2023-09-300001674862ash:AshlandDistributionMember2021-10-012022-09-300001674862ash:HerculesLimitedLiabilityCompanyMember2021-10-012022-09-300001674862us-gaap:NonUsMember2023-09-300001674862us-gaap:StockAppreciationRightsSARSMembersrt:MinimumMember2022-10-012023-09-300001674862ash:PersonalCareAndHouseholdMember2022-10-012023-09-300001674862us-gaap:OperatingSegmentsMemberash:PersonalCareAndHouseholdMember2022-10-012023-09-300001674862us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-10-012022-09-300001674862us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2022-10-012023-09-300001674862ash:ListedRealAssetsMemberus-gaap:FairValueInputsLevel3Member2022-09-3000016748622020-10-012020-12-310001674862us-gaap:FairValueInputsLevel1Memberash:InsuranceContractsMember2023-09-300001674862us-gaap:PerformanceSharesMember2022-09-300001674862us-gaap:PensionPlansDefinedBenefitMember2022-09-300001674862srt:MaximumMemberus-gaap:MachineryAndEquipmentMember2023-09-300001674862us-gaap:EquitySecuritiesMember2022-09-300001674862srt:MaximumMemberash:CreditAgreementMember2022-10-012023-09-300001674862ash:TermLoanAMember2021-10-012022-09-300001674862us-gaap:AdditionalPaidInCapitalMember2022-09-300001674862ash:LifeSciencesMember2022-09-300001674862us-gaap:OtherDebtSecuritiesMember2023-09-3000016748622023-07-012023-09-300001674862ash:TwoPointZeroZeroPercentageSeniorNotesDue2028Member2022-09-300001674862ash:ExercisePriceRange2Member2022-10-012023-09-300001674862ash:TwoThousandTwentyTwoCreditAgreementMember2021-10-012022-09-3000016748622020-01-012020-03-310001674862srt:MinimumMemberash:AffiliatesMember2023-09-300001674862ash:HerculesLimitedLiabilityCompanyMember2022-10-012023-09-300001674862us-gaap:FairValueInputsLevel2Memberash:InsuranceContractsMember2023-09-300001674862us-gaap:CommonStockMember2023-09-300001674862ash:OtherGovernmentSecuritiesMemberus-gaap:FairValueInputsLevel3Member2022-09-300001674862us-gaap:InventoryValuationReserveMember2020-09-300001674862us-gaap:InventoryValuationReserveMember2021-10-012022-09-300001674862ash:CashSettledNonvestedStockAwardsMember2020-10-012021-09-300001674862ash:PersonalCareMember2022-10-012023-09-300001674862us-gaap:IntersegmentEliminationMember2020-10-012021-09-300001674862us-gaap:ConstructionInProgressMember2022-09-300001674862us-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2022-09-300001674862us-gaap:StockCompensationPlanMember2022-09-300001674862ash:PersonalCareMembersrt:AsiaPacificMember2020-10-012021-09-300001674862ash:CompositesOrMarlFacilityMember2022-10-012023-09-300001674862us-gaap:RealEstateMember2021-10-012022-09-300001674862ash:CashSettledNonvestedStockAwardsMember2021-10-012022-09-300001674862us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-09-300001674862ash:TwoThousandTwentyThreeStockRepurchaseProgramMember2023-06-280001674862us-gaap:InventoryValuationReserveMember2022-10-012023-09-300001674862ash:AshlandGlobalHoldingsIncMember2022-09-300001674862ash:LifeSciencesMember2022-10-012023-09-300001674862us-gaap:BuildingMember2023-09-300001674862ash:SixPointEightSevenFivePercentageNotesDue2043Member2022-10-012023-09-300001674862us-gaap:AsbestosIssueMember2022-10-012023-09-300001674862us-gaap:CostOfSalesMember2021-10-012022-09-300001674862us-gaap:FairValueInputsLevel1Memberus-gaap:CorporateDebtSecuritiesMember2023-09-300001674862ash:TwoThousandTwentyTwoSockRepurchaseProgramMember2023-02-280001674862us-gaap:AdditionalPaidInCapitalMember2021-09-300001674862us-gaap:DemandDepositsMember2022-09-300001674862ash:LifeSciencesMembersrt:AsiaPacificMember2021-10-012022-09-300001674862us-gaap:StockAppreciationRightsSARSMember2020-10-012021-09-300001674862us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2020-10-012021-09-300001674862us-gaap:FairValueInputsLevel2Memberash:OtherGovernmentSecuritiesMember2022-09-300001674862ash:ThreePointThreeSevenFivePercentageSeniorNotesDue2031Member2022-09-300001674862us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-10-012021-09-300001674862us-gaap:FairValueInputsLevel2Memberus-gaap:CashAndCashEquivalentsMember2023-09-300001674862us-gaap:AllowanceForCreditLossMember2021-10-012022-09-300001674862us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2022-10-012023-09-300001674862us-gaap:ForeignPlanMember2023-09-300001674862ash:TwoThousandEighteenAssetBackedSecuritiesMember2021-07-012021-07-310001674862us-gaap:FairValueInputsLevel1Memberus-gaap:CommodityContractMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001674862us-gaap:StockAppreciationRightsSARSMember2020-09-300001674862ash:UnallocatedAndOtherMember2022-09-300001674862us-gaap:StockCompensationPlanMember2022-10-012023-09-3000016748622021-10-012022-09-300001674862ash:SpecialtyAdditivesMember2023-09-300001674862us-gaap:FairValueInputsLevel3Member2022-09-300001674862us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-10-012023-09-300001674862us-gaap:CustomerRelationshipsMembersrt:MaximumMember2023-09-300001674862us-gaap:StockCompensationPlanMember2023-09-300001674862us-gaap:CorporateDebtSecuritiesMember2023-09-300001674862ash:PlanassetallocationbyassettypeMember2022-10-012023-09-300001674862ash:FourPointSevenFiveZeroPercentageNotesDue2022Member2021-09-300001674862ash:IntermediatesMember2022-09-300001674862ash:PersonalCareMember2023-09-300001674862ash:LifeSciencesMemberash:LatinAmericaAndOtherMember2020-10-012021-09-300001674862us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001674862us-gaap:AdditionalPaidInCapitalMember2022-10-012023-09-300001674862us-gaap:TrademarksAndTradeNamesMember2023-09-300001674862srt:MinimumMember2023-09-300001674862us-gaap:OtherDebtSecuritiesMember2022-09-300001674862ash:RestrictedSecuritiesMember2022-09-300001674862ash:CashSettledNonvestedRestrictedStockAwardsMember2021-10-012022-09-300001674862ash:TwoThousandTwentyTwoSockRepurchaseProgramMember2022-09-300001674862us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberash:CreditAgreementMember2022-10-012023-09-300001674862us-gaap:RetainedEarningsMember2020-09-300001674862us-gaap:OperatingSegmentsMemberash:SpecialtyAdditivesMember2022-10-012023-09-300001674862us-gaap:StockCompensationPlanMember2020-09-300001674862us-gaap:FairValueInputsLevel2Memberus-gaap:EquitySecuritiesMember2023-09-300001674862us-gaap:CommodityContractMember2021-10-012022-09-300001674862ash:USAccountsReceivableSalesProgramMembersrt:MaximumMember2023-09-300001674862ash:CreditAgreementMemberash:AlternateBaseRateMember2023-09-300001674862ash:SpecialtyAdditivesMembersrt:EuropeMember2022-10-012023-09-300001674862us-gaap:AllowanceForCreditLossMember2022-10-012023-09-300001674862us-gaap:CostOfSalesMember2022-10-012023-09-300001674862ash:ThreePointThreeSevenFivePercentageSeniorNotesDue2031Member2021-10-012022-09-300001674862us-gaap:OtherLiabilitiesMemberus-gaap:CommodityContractMember2022-09-300001674862srt:NorthAmericaMemberash:PersonalCareMember2021-10-012022-09-300001674862us-gaap:FairValueInputsLevel3Memberash:InsuranceContractsMember2023-09-300001674862us-gaap:AsbestosIssueMember2021-10-012022-09-300001674862us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2020-10-012021-09-300001674862us-gaap:OperatingSegmentsMemberash:IntermediatesAndSolventsMember2020-10-012021-09-300001674862ash:TwoThousandEighteenStockRepurchaseProgramMember2022-03-010001674862us-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2022-09-300001674862us-gaap:TrademarksAndTradeNamesMember2022-09-3000016748622022-02-282022-02-280001674862ash:LifeSciencesMemberash:LatinAmericaAndOtherMember2021-10-012022-09-300001674862us-gaap:FairValueInputsLevel3Memberus-gaap:AssetBackedSecuritiesMember2022-09-300001674862us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-10-012022-09-300001674862us-gaap:StockCompensationPlanMember2021-10-012022-09-300001674862us-gaap:CashAndCashEquivalentsMember2023-09-300001674862us-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMember2021-10-012022-09-300001674862us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-09-300001674862ash:ThreePointThreeSevenFivePercentageSeniorNotesDue2031Member2023-09-300001674862us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMember2022-09-3000016748622023-01-012023-03-310001674862us-gaap:OtherDebtSecuritiesMembersrt:MinimumMember2023-09-300001674862us-gaap:OperatingSegmentsMemberash:PersonalCareAndHouseholdMember2021-10-012022-09-300001674862ash:TwoThousandTwentyTwoSockRepurchaseProgramMember2023-06-280001674862us-gaap:LandAndBuildingMemberash:CompositesSegmentAndIntermediatesAndSolventsMarlFacilityMember2022-09-300001674862us-gaap:CostOfSalesMember2020-10-012021-09-300001674862srt:MaximumMembercountry:US2021-10-012022-09-300001674862ash:EuriborMembersrt:MaximumMemberash:CreditAgreementMember2023-09-300001674862us-gaap:AllowanceForCreditLossMember2022-09-300001674862ash:RestructuringSeveranceCostsMember2021-09-300001674862us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300001674862ash:LifeSciencesMembersrt:EuropeMember2022-10-012023-09-300001674862us-gaap:CustomerRelationshipsMembersrt:MinimumMember2023-09-300001674862us-gaap:SalesRevenueNetMemberash:PolyvinylpyrrolidonesMemberus-gaap:ProductConcentrationRiskMember2022-10-012023-09-300001674862ash:PerformanceAdhesivesMember2020-10-012021-09-300001674862ash:GlobalIntangibleLowTaxedIncomeMember2022-10-012023-09-300001674862us-gaap:FairValueInputsLevel3Memberus-gaap:EquitySecuritiesMember2022-09-300001674862us-gaap:FairValueInputsLevel1Memberus-gaap:AssetBackedSecuritiesMember2023-09-300001674862us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001674862us-gaap:CommonStockMember2022-09-300001674862us-gaap:StockAppreciationRightsSARSMember2022-10-012023-09-300001674862ash:CreditAgreementMember2022-10-012023-09-3000016748622023-10-310001674862ash:IntermediatesMembersrt:EuropeMember2020-10-012021-09-300001674862ash:AshlandDistributionMember2022-10-012023-09-300001674862ash:SpecialtyAdditivesMembersrt:AsiaPacificMember2022-10-012023-09-300001674862us-gaap:FairValueInputsLevel2Memberus-gaap:AssetBackedSecuritiesMember2023-09-3000016748622022-10-012022-12-310001674862us-gaap:OtherPensionPlansPostretirementOrSupplementalPlansDefinedBenefitMember2022-10-012023-09-300001674862ash:TwoThousandTwentyTwoSockRepurchaseProgramMember2023-05-310001674862ash:SpecialtyAdditivesMember2021-10-012022-09-300001674862us-gaap:FairValueInputsLevel2Memberus-gaap:CommodityContractMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001674862us-gaap:LandMember2023-09-300001674862ash:TwoPointZeroZeroPercentageSeniorNotesDue2028Member2022-10-012023-09-300001674862srt:AsiaPacificMemberash:IntermediatesMember2021-10-012022-09-300001674862us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2023-09-300001674862srt:MaximumMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberash:CreditAgreementMember2023-09-300001674862ash:IntermediatesAndSolventsMember2021-10-012022-09-300001674862us-gaap:AccountsReceivableMemberus-gaap:CommodityContractMember2023-09-300001674862us-gaap:CustomerRelationshipsMember2023-09-300001674862us-gaap:RetainedEarningsMember2022-10-012023-09-300001674862us-gaap:PensionPlansDefinedBenefitMemberus-gaap:SegmentContinuingOperationsMember2021-10-012022-09-300001674862srt:NorthAmericaMemberash:IntermediatesMember2020-10-012021-09-300001674862ash:AsbestosTrustMember2022-09-300001674862ash:EuropeanFacilityMember2021-10-012022-09-300001674862us-gaap:ForeignPlanMember2022-10-012023-09-300001674862ash:PersonalCareMember2020-10-012021-09-300001674862ash:PersonalCareAndHouseholdMember2022-09-300001674862ash:RestructuringSeveranceCostsMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2022-10-012023-09-300001674862srt:MaximumMemberus-gaap:PerformanceSharesMember2022-10-012023-09-300001674862ash:AshlandGlobalHoldingsIncMemberus-gaap:OtherCurrentLiabilitiesMember2023-09-300001674862us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2021-10-012022-09-300001674862ash:SpecialtyAdditivesFacilityMembersrt:MaximumMemberus-gaap:DiscontinuedOperationsHeldforsaleMember2023-09-300001674862ash:PersonalCareAndHouseholdMember2023-09-300001674862ash:SpecialtyAdditivesMemberash:LatinAmericaAndOtherMember2022-10-012023-09-300001674862us-gaap:USGovernmentDebtSecuritiesMember2023-09-300001674862ash:TwoPointZeroZeroPercentageSeniorNotesDue2028Member2021-10-012022-09-300001674862srt:MinimumMemberus-gaap:StockCompensationPlanMember2022-10-012023-09-300001674862ash:SixPointEightSevenFivePercentageNotesDue2043Member2021-10-012022-09-3000016748622019-07-012019-09-300001674862srt:AsiaPacificMemberash:IntermediatesMember2022-10-012023-09-300001674862us-gaap:StockAppreciationRightsSARSMember2021-10-012022-09-300001674862us-gaap:NonUsMember2022-10-012023-09-300001674862us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2020-10-012021-09-300001674862ash:PerformanceAdhesivesMember2021-10-012022-09-300001674862us-gaap:RealEstateMember2022-10-012023-09-300001674862ash:HerculesLimitedLiabilityCompanyMember2020-10-012021-09-300001674862ash:RestructuringSeveranceCostsMember2022-09-300001674862ash:HerculesLimitedLiabilityCompanyMember2023-09-300001674862us-gaap:PensionPlansDefinedBenefitMember2020-10-012021-09-300001674862us-gaap:NonUsMember2022-09-300001674862us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001674862ash:IntermediatesMember2023-09-300001674862us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001674862ash:SpecialtyAdditivesMemberash:LatinAmericaAndOtherMember2020-10-012021-09-300001674862srt:MaximumMember2022-09-300001674862us-gaap:PensionPlansDefinedBenefitMember2022-10-012023-09-300001674862us-gaap:StateAndLocalJurisdictionMember2020-10-012021-09-300001674862ash:IntermediatesMember2021-10-012022-09-300001674862us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-10-012023-09-300001674862ash:OtherGovernmentSecuritiesMember2022-09-300001674862us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001674862ash:SpecialtyAdditivesMember2021-09-300001674862ash:UnallocatedAndOtherMember2020-10-012021-09-300001674862ash:SixPointFiveZeroPercentageJuniorSubordinatedNotesDue2029Member2023-09-300001674862us-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentDebtSecuritiesMember2023-09-300001674862ash:SpecialtyAdditivesMembersrt:NorthAmericaMember2021-10-012022-09-300001674862ash:TwoThousandEighteenAssetBackedSecuritiesMember2022-09-300001674862ash:CashSettledPerformanceSharesMember2021-10-012022-09-300001674862srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2021-09-300001674862us-gaap:CorporateDebtSecuritiesMember2022-09-300001674862us-gaap:DebtSecuritiesMember2023-09-300001674862us-gaap:FairValueInputsLevel2Memberus-gaap:EquitySecuritiesMember2022-09-300001674862ash:RestructuringSeveranceCostsTwoMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2022-10-012023-09-300001674862us-gaap:StockCompensationPlanMember2020-10-012021-09-300001674862us-gaap:OperatingSegmentsMemberash:LifeSciencesMember2020-10-012021-09-300001674862us-gaap:OtherPensionPlansPostretirementOrSupplementalPlansDefinedBenefitMember2023-09-300001674862us-gaap:RetainedEarningsMember2023-09-300001674862us-gaap:FairValueInputsLevel2Memberash:ListedRealAssetsMember2023-09-300001674862ash:SpecialtyAdditivesMembersrt:AsiaPacificMember2020-10-012021-09-300001674862us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001674862ash:ExercisePriceRange2Member2023-09-300001674862ash:HerculesLimitedLiabilityCompanyMemberus-gaap:OtherCurrentLiabilitiesMember2023-09-300001674862us-gaap:AccountsReceivableMemberus-gaap:ForeignExchangeContractMember2023-09-300001674862us-gaap:AccountsReceivableMemberash:AshlandGlobalHoldingsIncMember2022-09-300001674862country:US2023-09-300001674862ash:InsuranceContractsMember2022-09-300001674862us-gaap:FairValueInputsLevel3Memberus-gaap:CorporateDebtSecuritiesMember2023-09-300001674862srt:MinimumMemberus-gaap:DebtSecuritiesMember2023-09-300001674862srt:NorthAmericaMemberash:PersonalCareMember2020-10-012021-09-300001674862us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001674862srt:MaximumMemberus-gaap:EquitySecuritiesMember2023-09-300001674862us-gaap:PensionPlansDefinedBenefitMemberus-gaap:SegmentContinuingOperationsMember2021-09-300001674862ash:InsuranceContractsMember2023-09-300001674862ash:LifeSciencesMembersrt:EuropeMember2021-10-012022-09-300001674862ash:IntermediatesMember2020-10-012021-09-300001674862us-gaap:AccountingStandardsUpdate201613Member2022-10-012023-09-300001674862srt:MaximumMemberash:CreditAgreementMemberash:AlternateBaseRateMember2023-09-300001674862ash:TwoThousandTwentyOneAcceleratedShareRepurchaseAgreementMember2022-10-012023-09-300001674862us-gaap:AccountingStandardsUpdate201613Member2023-09-300001674862ash:WaterTechnologiesMember2020-10-012021-09-300001674862us-gaap:FixedIncomeSecuritiesMember2023-09-300001674862srt:AsiaPacificMemberash:IntermediatesMember2020-10-012021-09-300001674862ash:RestructuringSeveranceCostsThreeMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2020-10-012021-09-300001674862us-gaap:LandAndBuildingMemberash:CompositesSegmentAndIntermediatesAndSolventsMarlFacilityMember2023-09-300001674862ash:BetweenFebruaryAndOctoberOfEachYearMemberash:USAccountsReceivableSalesProgramMember2021-03-172021-03-170001674862us-gaap:ForeignCountryMember2021-09-300001674862us-gaap:StockAppreciationRightsSARSMembersrt:MaximumMember2022-10-012023-09-300001674862us-gaap:SellingGeneralAndAdministrativeExpensesMember2020-10-012021-09-300001674862ash:OtherGovernmentSecuritiesMemberus-gaap:FairValueInputsLevel3Member2023-09-300001674862us-gaap:AdditionalPaidInCapitalMember2023-09-300001674862ash:FourPointSevenFiveZeroPercentageSeniorNotesDue2022Member2020-01-310001674862us-gaap:AdditionalPaidInCapitalMember2020-09-300001674862ash:SpecialtyAdditivesMembersrt:AsiaPacificMember2021-10-012022-09-300001674862us-gaap:InventoryValuationReserveMember2022-09-300001674862ash:SpecialtyAdditivesFacilityMember2022-10-012023-09-300001674862us-gaap:OtherPensionPlansPostretirementOrSupplementalPlansDefinedBenefitMember2020-10-012021-09-300001674862us-gaap:FairValueInputsLevel3Memberus-gaap:EquitySecuritiesMember2023-09-3000016748622021-01-012021-03-310001674862us-gaap:FairValueInputsLevel1Memberus-gaap:CashAndCashEquivalentsMember2023-09-3000016748622021-04-012021-06-300001674862ash:PersonalCareMembersrt:EuropeMember2022-10-012023-09-300001674862ash:AshlandGlobalHoldingsIncMember2023-09-300001674862ash:TwoThousandTwentyOneAcceleratedShareRepurchaseAgreementMember2021-09-012021-09-300001674862us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001674862us-gaap:IntellectualPropertyMember2023-09-300001674862srt:MinimumMemberus-gaap:MachineryAndEquipmentMember2023-09-300001674862ash:PersonalCareMembersrt:AsiaPacificMember2021-10-012022-09-300001674862ash:ValvolineIncMember2021-10-012022-09-300001674862country:US2021-10-012022-09-300001674862us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2021-10-012022-09-300001674862us-gaap:PerformanceSharesMember2021-09-300001674862ash:SpecialtyAdditivesMemberash:LatinAmericaAndOtherMember2021-10-012022-09-300001674862us-gaap:FairValueInputsLevel2Member2023-09-300001674862us-gaap:PerformanceSharesMember2020-10-012021-09-300001674862ash:USAccountsReceivableSalesProgramMemberash:PerformanceAdhesivesMember2021-10-012022-09-300001674862us-gaap:FairValueInputsLevel2Memberash:InsuranceContractsMember2022-09-300001674862ash:LifeSciencesMemberash:LatinAmericaAndOtherMember2022-10-012023-09-300001674862us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2020-09-300001674862us-gaap:OtherDebtSecuritiesMembersrt:MaximumMember2023-09-300001674862ash:CompositesOrMarlFacilityMember2020-10-012021-09-300001674862ash:SpecialtyAdditivesMembersrt:NorthAmericaMember2020-10-012021-09-300001674862ash:ExercisePriceRange1Member2023-09-300001674862ash:PersonalCareMemberash:LatinAmericaAndOtherMember2022-10-012023-09-300001674862ash:HerculesLimitedLiabilityCompanyMember2020-09-300001674862us-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMember2020-10-012021-09-300001674862us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMember2023-09-300001674862ash:FourPointSevenFiveZeroPercentageNotesDue2022Member2020-10-012021-09-300001674862us-gaap:PensionPlansDefinedBenefitMemberus-gaap:SegmentContinuingOperationsMember2022-10-012023-09-300001674862ash:IntermediatesAndSolventsMember2023-09-300001674862us-gaap:FairValueInputsLevel1Memberus-gaap:CashAndCashEquivalentsMember2022-09-300001674862ash:SixPointFiveZeroPercentageJuniorSubordinatedNotesDue2029Member2022-09-300001674862srt:NorthAmericaMemberash:PersonalCareMember2022-10-012023-09-300001674862us-gaap:FairValueInputsLevel2Member2022-09-300001674862ash:TwoThousandEighteenStockRepurchaseProgramMember2022-03-012022-03-010001674862ash:SpecialtyAdditivesMembersrt:NorthAmericaMember2022-10-012023-09-300001674862us-gaap:TrademarksAndTradeNamesMembersrt:MaximumMember2023-09-300001674862ash:PersonalCareMemberash:LatinAmericaAndOtherMember2021-10-012022-09-300001674862srt:NorthAmericaMemberash:IntermediatesMember2021-10-012022-09-300001674862us-gaap:FairValueInputsLevel2Memberash:OtherGovernmentSecuritiesMember2023-09-300001674862us-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMember2022-10-012023-09-300001674862us-gaap:AllowanceForCreditLossMember2023-09-300001674862ash:TwoThousandTwentyTwoSockRepurchaseProgramMember2023-02-012023-02-280001674862srt:MaximumMemberus-gaap:StockCompensationPlanMember2022-10-012023-09-3000016748622019-04-012019-06-300001674862us-gaap:LandMember2022-09-300001674862ash:AsbestosTrustMember2023-09-300001674862ash:AshlandGlobalHoldingsIncMember2021-09-300001674862us-gaap:CommodityContractMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001674862srt:MaximumMemberus-gaap:IntellectualPropertyMember2023-09-300001674862us-gaap:CommonStockMember2020-09-300001674862us-gaap:CommodityContractMember2022-10-012023-09-300001674862us-gaap:RetainedEarningsMembersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2021-09-300001674862srt:MaximumMemberash:AffiliatesMember2023-09-300001674862us-gaap:CommodityContractMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001674862ash:UnallocatedAndOtherMember2022-10-012023-09-300001674862ash:LifeSciencesMembersrt:AsiaPacificMember2020-10-012021-09-300001674862us-gaap:FairValueInputsLevel2Memberus-gaap:CommodityContractMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001674862us-gaap:PensionPlansDefinedBenefitMember2021-10-012022-09-3000016748622021-10-012021-12-310001674862ash:SpecialtyAdditivesMember2022-10-012023-09-300001674862ash:IntermediatesAndSolventsMember2020-10-012021-09-300001674862country:US2022-10-012023-09-300001674862us-gaap:StockAppreciationRightsSARSMember2022-09-300001674862us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:CommodityContractMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001674862ash:USAccountsReceivableSalesProgramMember2023-04-142023-04-140001674862us-gaap:LandAndBuildingMemberash:CompositesSegmentAndIntermediatesAndSolventsMarlFacilityMember2021-10-012022-09-300001674862ash:TwoThousandEighteenAssetBackedSecuritiesMember2019-09-012019-09-300001674862ash:UnsecuredRevolvingCreditFacilityMemberash:TwoThousandTwentyTwoCreditAgreementMember2022-07-012022-07-310001674862us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:SegmentContinuingOperationsMember2023-09-300001674862us-gaap:MachineryAndEquipmentMember2023-09-300001674862us-gaap:SalesRevenueNetMembersrt:MinimumMemberus-gaap:ProductConcentrationRiskMember2022-10-012023-09-300001674862us-gaap:AllowanceForCreditLossMember2020-09-300001674862ash:SubpartFMember2022-10-012023-09-300001674862ash:CashSettledPerformanceSharesMember2020-10-012021-09-300001674862ash:ThreePointThreeSevenFivePercentageSeniorNotesDue2031Member2021-08-012021-08-310001674862us-gaap:ConstructionInProgressMember2023-09-3000016748622022-04-012022-06-300001674862us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2023-09-300001674862us-gaap:NonUsMember2020-10-012021-09-300001674862ash:RestructuringSeveranceCostsThreeMember2022-09-300001674862ash:AshlandGlobalHoldingsIncMember2021-10-012022-09-300001674862srt:NorthAmericaMemberash:LifeSciencesMember2020-10-012021-09-300001674862us-gaap:PerformanceSharesMember2023-09-300001674862us-gaap:FairValueInputsLevel1Memberus-gaap:EquitySecuritiesMember2022-09-3000016748622020-09-300001674862us-gaap:AccountingStandardsUpdate201613Memberus-gaap:RetainedEarningsMembersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2023-09-300001674862us-gaap:InventoryValuationReserveMember2023-09-300001674862us-gaap:NonUsMember2021-10-012022-09-300001674862ash:TwoThousandTwentyOneAcceleratedShareRepurchaseAgreementMember2022-02-012022-02-280001674862us-gaap:SalesRevenueNetMemberash:CellulosicsMemberus-gaap:ProductConcentrationRiskMember2022-10-012023-09-300001674862ash:AccruedExpensesAndOtherLiabilitiesMemberash:RestructuringSeveranceCostsMember2023-09-300001674862ash:LifeSciencesMember2023-09-300001674862us-gaap:TrademarksAndTradeNamesMembersrt:MinimumMember2023-09-300001674862us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2021-10-012022-09-300001674862us-gaap:PensionPlansDefinedBenefitMember2023-09-300001674862srt:MinimumMemberus-gaap:PerformanceSharesMember2022-10-012023-09-300001674862srt:NorthAmericaMemberash:LifeSciencesMember2022-10-012023-09-300001674862us-gaap:PerformanceSharesMember2021-10-012022-09-300001674862ash:NotesDue2022Member2020-10-012021-09-300001674862us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:SegmentContinuingOperationsMember2022-10-012023-09-300001674862ash:LifeSciencesMember2021-09-300001674862ash:AsbestosTrustMember2014-10-012015-09-300001674862ash:ThreePointThreeSevenFivePercentageSeniorNotesDue2031Member2021-08-310001674862us-gaap:FairValueInputsLevel1Memberus-gaap:AssetBackedSecuritiesMember2022-09-3000016748622021-09-300001674862ash:GlobalIntangibleLowTaxedIncomeMember2021-10-012022-09-300001674862ash:HerculesLimitedLiabilityCompanyMemberus-gaap:AccountsReceivableMember2023-09-300001674862ash:ValvolineIncMember2022-10-012023-09-300001674862country:US2020-10-012021-09-300001674862us-gaap:RetainedEarningsMember2021-10-012022-09-300001674862srt:NorthAmericaMemberash:LifeSciencesMember2021-10-012022-09-300001674862ash:SixPointFiveZeroPercentageJuniorSubordinatedNotesDue2029Member2021-10-012022-09-300001674862ash:RestructuringSeveranceCostsMember2023-09-300001674862us-gaap:IntersegmentEliminationMember2021-10-012022-09-3000016748622021-07-012021-09-300001674862ash:PersonalCareMember2021-09-300001674862us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2022-09-300001674862us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:SegmentContinuingOperationsMember2021-09-300001674862ash:LatinAmericaAndOtherMemberash:IntermediatesMember2021-10-012022-09-300001674862ash:USAccountsReceivableSalesProgramMember2021-03-172021-03-170001674862us-gaap:BuildingMember2022-09-300001674862ash:WaterTechnologiesMember2021-10-012022-09-300001674862us-gaap:OtherPensionPlansPostretirementOrSupplementalPlansDefinedBenefitMember2022-09-300001674862ash:PersonalCareAndHouseholdMember2021-10-012022-09-300001674862ash:OtherDebtMember2022-09-300001674862us-gaap:FairValueInputsLevel1Memberus-gaap:CommodityContractMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001674862ash:ListedRealAssetsMember2023-09-300001674862us-gaap:OtherPensionPlansPostretirementOrSupplementalPlansDefinedBenefitMember2021-10-012022-09-300001674862ash:EuriborMembersrt:MinimumMemberash:CreditAgreementMember2023-09-300001674862ash:AshlandGlobalHoldingsIncMemberus-gaap:AccountsReceivableMember2023-09-300001674862ash:IntermediatesMember2022-10-012023-09-300001674862us-gaap:FairValueInputsLevel2Memberus-gaap:AssetBackedSecuritiesMember2022-09-300001674862us-gaap:MachineryAndEquipmentMember2022-09-300001674862us-gaap:AccountsReceivableMemberus-gaap:CommodityContractMember2022-09-300001674862us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2022-09-300001674862us-gaap:FairValueInputsLevel3Memberash:InsuranceContractsMember2022-09-300001674862us-gaap:InventoryValuationReserveMember2021-09-300001674862us-gaap:FairValueInputsLevel1Memberash:OtherGovernmentSecuritiesMember2022-09-300001674862srt:MaximumMemberus-gaap:BuildingMember2023-09-300001674862ash:PersonalCareMembersrt:EuropeMember2020-10-012021-09-3000016748622023-04-012023-06-300001674862ash:LifeSciencesMember2020-10-012021-09-300001674862ash:OtherDebtMember2023-09-300001674862us-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2023-09-300001674862us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-09-300001674862ash:PlanAssetFairValueHeirarchyMember2022-10-012023-09-300001674862us-gaap:StateAndLocalJurisdictionMember2021-10-012022-09-300001674862ash:ValvolineIncMember2020-10-012021-09-300001674862ash:FourPointSevenFiveZeroPercentageSeniorNotesDue2022Member2020-01-012020-01-310001674862ash:ThreePointThreeSevenFivePercentageSeniorNotesDue2031Member2022-10-012023-09-300001674862us-gaap:AccountsReceivableMemberus-gaap:ForeignExchangeContractMember2022-09-300001674862ash:UnallocatedAndOtherMember2023-09-300001674862ash:TwoThousandEighteenAssetBackedSecuritiesMember2020-07-310001674862us-gaap:AdditionalPaidInCapitalMember2020-10-012021-09-300001674862us-gaap:FairValueInputsLevel1Memberus-gaap:EquitySecuritiesMember2023-09-300001674862us-gaap:OperatingSegmentsMemberash:IntermediatesAndSolventsMember2022-10-012023-09-300001674862srt:MinimumMemberus-gaap:IntellectualPropertyMember2023-09-300001674862ash:LifeSciencesMembersrt:EuropeMember2020-10-012021-09-300001674862ash:RestructuringSeveranceCostsThreeMember2023-09-300001674862us-gaap:AllowanceForCreditLossMember2020-10-012021-09-300001674862ash:PersonalCareMembersrt:EuropeMember2021-10-012022-09-300001674862ash:CashSettledNonvestedRestrictedStockAwardsMember2020-10-012021-09-3000016748622022-01-012022-03-310001674862us-gaap:IntellectualPropertyMember2022-09-300001674862ash:AshlandGlobalHoldingsIncMember2022-10-012023-09-300001674862ash:RestructuringSeveranceCostsMember2022-10-012023-09-300001674862ash:SpecialtyAdditivesMembersrt:EuropeMember2021-10-012022-09-300001674862us-gaap:OtherLiabilitiesMemberus-gaap:CommodityContractMember2023-09-300001674862ash:PerformanceAdhesivesMember2022-10-012023-09-300001674862ash:SixPointFiveZeroPercentageJuniorSubordinatedNotesDue2029Member2022-10-012023-09-300001674862us-gaap:InventoryValuationReserveMember2020-10-012021-09-300001674862us-gaap:TradeAccountsReceivableMember2022-09-300001674862us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001674862ash:HerculesLimitedLiabilityCompanyMember2021-09-300001674862ash:UnallocatedAndOtherMember2021-10-012022-09-300001674862ash:IntermediatesMember2021-09-300001674862us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2020-09-300001674862us-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2023-09-300001674862ash:AshlandGlobalHoldingsIncMember2020-10-012021-09-300001674862ash:EnvironmentalTrustMember2023-09-300001674862us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2021-09-3000016748622020-04-012020-06-300001674862ash:PersonalCareAndHouseholdMember2020-10-012021-09-300001674862us-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel3Member2023-09-300001674862us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2021-09-300001674862us-gaap:CashAndCashEquivalentsMember2022-09-300001674862us-gaap:PensionPlansDefinedBenefitMemberus-gaap:SegmentContinuingOperationsMember2022-09-300001674862country:US2022-09-300001674862country:US2023-09-300001674862ash:WaterTechnologiesMember2022-10-012023-09-300001674862us-gaap:EquityFundsMember2022-09-300001674862us-gaap:OperatingSegmentsMemberash:LifeSciencesMember2022-10-012023-09-300001674862ash:LatinAmericaAndOtherMemberash:IntermediatesMember2020-10-012021-09-300001674862us-gaap:ForeignCountryMember2020-10-012021-09-300001674862us-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel3Member2022-09-300001674862ash:SpecialtyAdditivesMember2020-10-012021-09-300001674862us-gaap:FairValueInputsLevel1Memberash:ListedRealAssetsMember2022-09-300001674862ash:SpecialtyAdditivesFacilityMemberus-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:DiscontinuedOperationsHeldforsaleMember2022-10-012023-09-300001674862us-gaap:RetainedEarningsMember2020-10-012021-09-300001674862us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2022-10-012023-09-300001674862us-gaap:OperatingSegmentsMemberash:SpecialtyAdditivesMember2020-10-012021-09-300001674862us-gaap:AdditionalPaidInCapitalMember2021-10-012022-09-300001674862ash:ListedRealAssetsMemberus-gaap:FairValueInputsLevel3Member2023-09-300001674862ash:RestructuringSeveranceCostsThreeMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2021-10-012022-09-300001674862us-gaap:StockAppreciationRightsSARSMember2023-09-300001674862us-gaap:RetainedEarningsMember2021-09-300001674862us-gaap:FairValueInputsLevel3Memberus-gaap:CommodityContractMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001674862us-gaap:FairValueInputsLevel1Member2023-09-300001674862us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2023-09-300001674862us-gaap:SubsequentEventMemberash:AshlandGlobalHoldingsIncMember2023-10-192023-10-190001674862ash:EnvironmentalTrustMember2022-09-300001674862us-gaap:StockAppreciationRightsSARSMember2021-09-300001674862ash:HerculesLimitedLiabilityCompanyMemberus-gaap:AccountsReceivableMember2022-09-300001674862us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:CommodityContractMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001674862us-gaap:StateAndLocalJurisdictionMember2023-09-300001674862ash:SixPointEightSevenFivePercentageNotesDue2043Member2022-09-300001674862us-gaap:IntersegmentEliminationMember2022-10-012023-09-300001674862srt:MaximumMemberus-gaap:DebtSecuritiesMember2023-09-300001674862us-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueInputsLevel3Member2023-09-300001674862ash:HerculesLimitedLiabilityCompanyMember2022-09-300001674862ash:GlobalIntangibleLowTaxedIncomeMember2020-10-012021-09-300001674862srt:MinimumMemberash:CreditAgreementMember2022-10-012023-09-300001674862ash:TwoThousandTwentyTwoSockRepurchaseProgramMember2023-06-012023-06-300001674862country:US2022-10-012023-09-300001674862ash:USAccountsReceivableSalesProgramMember2021-10-012022-09-300001674862srt:MaximumMember2023-09-300001674862us-gaap:AsbestosIssueMember2020-10-012021-09-300001674862us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:SegmentContinuingOperationsMember2022-09-300001674862ash:CashSettledNonvestedStockAwardsMember2022-10-012023-09-300001674862ash:CashSettledNonvestedRestrictedStockAwardsMember2022-10-012023-09-300001674862us-gaap:OperatingSegmentsMemberash:SpecialtyAdditivesMember2021-10-012022-09-300001674862ash:USAccountsReceivableSalesProgramMember2022-10-012023-09-300001674862us-gaap:LandAndBuildingMemberash:CompositesSegmentAndIntermediatesAndSolventsMarlFacilityMember2021-09-300001674862us-gaap:ForeignCountryMember2023-09-300001674862ash:LatinAmericaAndOtherMemberash:IntermediatesMember2022-10-012023-09-300001674862ash:CashSettledPerformanceSharesMember2022-10-012023-09-300001674862us-gaap:OperatingSegmentsMemberash:LifeSciencesMember2021-10-012022-09-300001674862ash:BetweenAprilAndOctoberOfEachYearMemberash:USAccountsReceivableSalesProgramMember2023-04-142023-04-140001674862us-gaap:FairValueInputsLevel1Member2022-09-300001674862ash:AshlandDistributionMember2020-10-012021-09-300001674862ash:TwoThousandEighteenAssetBackedSecuritiesMember2018-07-310001674862us-gaap:AllowanceForCreditLossMember2021-09-300001674862ash:PersonalCareMemberash:LatinAmericaAndOtherMember2020-10-012021-09-300001674862us-gaap:ForeignPlanMember2021-10-012022-09-300001674862ash:RestructuringSeveranceCostsMember2021-10-012022-09-300001674862ash:LifeSciencesMember2021-10-012022-09-300001674862ash:HerculesLimitedLiabilityCompanyMemberus-gaap:OtherCurrentLiabilitiesMember2022-09-300001674862us-gaap:FairValueInputsLevel1Memberash:OtherGovernmentSecuritiesMember2023-09-300001674862ash:RestructuringSeveranceCostsTwoMember2023-09-300001674862us-gaap:FairValueInputsLevel1Memberash:ListedRealAssetsMember2023-09-300001674862ash:SpecialtyAdditivesFacilityMemberus-gaap:DiscontinuedOperationsHeldforsaleMember2022-09-300001674862ash:SpecialtyAdditivesMember2022-09-3000016748622022-10-012023-09-300001674862us-gaap:PerformanceSharesMember2020-09-300001674862ash:CompositesOrMarlFacilityMember2021-10-012022-09-300001674862ash:A2017RevolvingCreditFacilityMember2021-10-012022-09-300001674862us-gaap:FairValueInputsLevel3Memberus-gaap:CommodityContractMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001674862ash:AshlandGlobalHoldingsIncMemberus-gaap:OtherCurrentLiabilitiesMember2022-09-300001674862ash:IntermediatesAndSolventsMember2022-09-300001674862us-gaap:FairValueInputsLevel3Member2023-09-300001674862us-gaap:LandAndBuildingMemberash:CompositesSegmentAndIntermediatesAndSolventsMarlFacilityMember2022-10-012023-09-300001674862us-gaap:FixedIncomeSecuritiesMember2022-09-300001674862us-gaap:FairValueInputsLevel2Memberus-gaap:CashAndCashEquivalentsMember2022-09-300001674862ash:SpecialtyAdditivesMembersrt:EuropeMember2020-10-012021-09-3000016748622020-10-012021-09-300001674862us-gaap:CommodityContractMember2020-10-012021-09-300001674862ash:OtherGovernmentSecuritiesMember2023-09-300001674862ash:TwoPointZeroZeroPercentageSeniorNotesDue2028Member2023-09-300001674862ash:EuriborMemberash:CreditAgreementMember2023-09-300001674862us-gaap:DemandDepositsMember2023-09-3000016748622023-09-300001674862ash:TwoThousandEighteenAssetBackedSecuritiesMember2018-07-302018-07-310001674862ash:SixPointEightSevenFivePercentageNotesDue2043Member2023-09-300001674862us-gaap:TradeAccountsReceivableMember2023-09-30iso4217:EURash:Claimxbrli:pureiso4217:USDxbrli:sharesash:Sitexbrli:sharesash:Employeeash:ServiceStationPropertyash:Facilityash:Propertyiso4217:USD

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-K

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended September 30, 2023

OR

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from _________ to ___________

Commission file number 333-211719

ASHLAND INC.

 

Delaware

(State or other jurisdiction of incorporation or organization)

81-2587835

(I.R.S. Employer Identification No.)

 

8145 Blazer Drive

Wilmington, Delaware 19808

Telephone Number (302) 995-3000

Securities Registered Pursuant to Section 12(b) of the Act:

 

Title of each class

Trading Symbol

Name of each exchange on which registered

Common Stock, par value $.01 per share

ASH

New York Stock Exchange

 

Securities Registered Pursuant to Section 12(g) of the Act: None

Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☑ No ☐

Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☑ No ☐

Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files). Yes ☑ No ☐

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large Accelerated Filer ☑

Accelerated Filer ☐

Non-Accelerated Filer ☐

Smaller Reporting Company

Emerging Growth Company

 

 

If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the Registrant has filed a report on attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under section 404(b) of the Sarbanes-Oxley Act (15 U.S.C 7262 (b)) by the registered public accounting firm that prepared or issued its audit report. Yes No ☐

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the Registrant included in the filing reflect the correction of an error to previously issued financial statements.

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the Registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No

At March 31, 2023, the aggregate market value of voting and non-voting common equity held by non-affiliates of the Registrant was approximately $5.4 billion. In determining this amount, the Registrant has assumed that its directors and executive officers are affiliates. Such assumption shall not be deemed conclusive for any other purpose.

At October 31, 2023, there were 51,259,852 shares of Registrant’s common stock outstanding.

 


 

DOCUMENTS INCORPORATED BY REFERENCE

Portions of Registrant’s Proxy Statement (Proxy Statement) for its 2024 Annual Meeting of Stockholders are incorporated by reference into Part III of this Annual Report on Form 10-K to the extent described herein.

 

 


 

TABLE OF CONTENTS

 

 

 

 

Page

PART I

 

 

 

 

Item 1.

Business

4

 

 

General

4

 

 

Life Sciences

5

 

 

Personal Care

5

 

 

Specialty Additives

6

 

 

Intermediates

7

 

 

Miscellaneous

7

 

Item 1A.

Risk Factors

13

 

Item 1B.

Unresolved Staff Comments

21

 

Item 1C.

Cybersecurity

21

 

Item 2.

Properties

21

 

Item 3.

Legal Proceedings

22

 

Item 4.

Mine Safety Disclosures

23

 

 

 

 

PART II

 

 

 

 

Item 5.

Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

24

 

Item 6.

[Reserved]

25

 

Item 7.

Management’s Discussion and Analysis of Financial Condition and Results of Operation

25

 

Item 7A.

Quantitative and Qualitative Disclosures about Market Risk

25

 

Item 8.

Financial Statements and Supplementary Data

25

 

Item 9.

Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

25

 

Item 9A.

Controls and Procedures

25

 

Item 9B.

Other Information

25

 

Item 9C.

Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

26

 

 

 

 

PART III

 

 

 

 

Item 10.

Directors, Executive Officers and Corporate Governance

27

 

Item 11.

Executive Compensation

27

 

Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

27

 

Item 13.

Certain Relationships and Related Transactions, and Director Independence

28

 

Item 14.

Principal Accountant Fees and Services

29

 

 

 

 

PART IV

 

 

 

 

Item 15.

Exhibits and Financial Statement Schedules

30

 

Item 16.

Form 10-K Summary

38

 

 


 

PART I

ITEM 1. BUSINESS

GENERAL

Ashland Inc. is a Delaware corporation, with its headquarters and principal executive offices at 8145 Blazer Drive, Wilmington, Delaware 19808. The terms “Ashland” and the “Company” as used herein include Ashland Inc., its predecessors, and its consolidated subsidiaries, except where the context indicates otherwise.

Ashland is a global specialty additives and materials company with a conscious and proactive mindset for sustainability. The company serves customers in a wide range of consumer and industrial markets including, architectural coatings, construction, energy, food and beverage, nutraceuticals, personal care and pharmaceutical. With approximately 3,800 employees worldwide, Ashland serves customers in more than 100 countries.

Ashland’s reportable segments include: Life Sciences; Personal Care (formerly Personal Care and Household); Specialty Additives; and Intermediates (formerly Intermediates and Solvents). Unallocated and Other includes corporate governance activities and certain legacy matters.

Life Sciences is comprised of pharmaceuticals, nutrition, nutraceuticals, agricultural chemicals, diagnostic films (formerly known as advanced materials) and fine chemicals. Pharmaceutical solutions include controlled release polymers, disintegrants, tablet coatings, thickeners, solubilizers and tablet binders. Nutrition solutions include thickeners, stabilizers, emulsifiers and additives for enhancing mouthfeel, controlling moisture migration, reducing oil uptake and binding structured foods. Nutraceutical solutions include products for weight management, joint comfort, stomach and intestinal health, sports nutrition and general wellness. The nutraceutical business also provides custom formulation, toll processing and particle engineering solutions. Customers include pharmaceutical, food, beverage, nutraceuticals and supplements manufacturers, hospitals and radiologists and industrial manufacturers.

Personal Care is comprised of biofunctionals, microbial protectants (preservatives), skin care, sun care, oral care, hair care and household solutions. These businesses have a broad range of natural, nature-derived, biodegradable, and high-performance ingredients for customer-driven solutions to help protect, renew, moisturize and revitalize skin and hair, and provide solutions for toothpastes, mouth washes and rinses, denture cleaning and care for teeth. Household supplies nature-derived rheology ingredients, biodegradable surface wetting agents, performance encapsulates, and specialty polymers for household, industrial and institutional cleaning products. Customers include formulators at large multinational branded consumer products companies and smaller, independent boutique companies.

Specialty Additives is comprised of rheology and performance-enhancing additives serving the architectural coatings, construction, energy, automotive and various industrial markets. Solutions include coatings additives for architectural paints, finishes and lacquers, cement- and gypsum- based dry mortars, ready-mixed joint compounds, synthetic plasters for commercial and residential construction, and specialty materials for industrial applications. Products include rheology modifiers (cellulosic and associative thickeners), foam control agents, surfactants and wetting agents, pH neutralizers, advanced ceramics used in catalytic converters, and environmental filters, ingredients that aid the manufacturing process of ceramic capacitors, plasma display panels and solar cells, ingredients for textile printing, thermoplastic metals and alloys for welding. Products help improve desired functional outcomes through rheology modification and control, water retention, workability, adhesive strength, binding power, film formation, deposition and suspension and emulsification. Customers include global paint manufacturers, electronics and automotive manufacturers, textile mills, the construction industry and welders.

Intermediates is comprised of the production of 1,4 butanediol (BDO) and related derivatives, including n-methylpyrrolidone. These products are used as chemical intermediates in the production of engineering polymers and polyurethanes, and as specialty process solvents in a wide array of applications including electronics, pharmaceuticals, water filtration membranes and more. BDO is also supplied to Life Sciences, Personal Care, and Specialty Additives for use as a raw material.

Unallocated and Other generally includes items such as certain significant company-wide restructuring activities, corporate governance costs and legacy costs or activities that relate to divested businesses that are no longer operated by Ashland.

4


 

Available Information - Ashland’s Internet address is http://www.ashland.com. On this website, Ashland makes available, free of charge, its annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and any amendments to those reports, as well as any beneficial ownership reports of officers and directors filed on Forms 3, 4 and 5. All such reports are available as soon as reasonably practicable after they are electronically filed with, or electronically furnished to, the Securities and Exchange Commission (SEC). Ashland also makes available, free of charge on its website, its Corporate Governance Guidelines, Board Committee Charters, Director Independence Standards and global code of conduct that applies to Ashland’s directors, officers and employees. These documents are also available in print to any stockholder who requests them. Information contained on Ashland’s website referenced here or elsewhere in this Annual Report is not part of this Annual Report on Form 10-K and is not incorporated by reference in this document. The SEC maintains an Internet site (http://www.sec.gov) that contains reports, proxy and information statements and other information regarding issuers that file electronically with the SEC.

LIFE SCIENCES

Life Sciences is a leading supplier of excipients and tablet coating systems to the pharmaceutical, nutrition and nutraceutical industries. Excipients include a comprehensive range of polymers for use as tablet binders, super disintegrants, sustained-release agents and drug solubilizers, as well as a variety of coating formulations for immediate, delayed, and sustained release applications. Core products include cellulosics and vinyl pyrrolidone polymers which are used primarily in oral solid dosage drug formulations. The portfolio also includes branded and proprietary nutraceutical ingredients and expertise in nutraceutical formulation, particle engineering and contract manufacturing. Its nutrition portfolio provides functional benefits in areas such as thickening, texture control, thermal gelation, structure enhancement, water binding, clarification and stabilization. Its core products include cellulose gums and vinyl pyrrolidone polymers which are used in a wide range of offerings for bakery, beverage, dairy, desserts, meat products, pet food, prepared foods, sauces and savory products.

Life Sciences operates throughout the Americas, Europe and Asia Pacific. It has 19 manufacturing and lab facilities in nine countries which serve its various end markets. It has manufacturing facilities and labs in Wilmington, Delaware; Calvert City, Kentucky; Kearny, and Totowa, New Jersey; Columbus, Ohio; Fiskeville, Rhode Island; Texas City, Texas; and Ogden, Utah within the United States; Cabreuva and Sao Paolo, Brazil; Shanghai, China; Dusseldorf, Germany; Hyderabad, India; Mullingar, Ireland; Jaumave (2 manufacturing facilities) and Mexico City, Mexico; Bangkok, Thailand; and Istanbul, Turkey.

Life Science markets and distributes its products in the Americas, Europe, the Middle East, Africa and Asia Pacific.

For fiscal 2023, the following Life Sciences product categories were 10% or greater of Ashland’s total consolidated sales:

Product

% of Life Sciences sales

% of Ashland total consolidated sales

Cellulosics

34%

37%

Polyvinylpyrrolidones (PVP)

44%

25%

PERSONAL CARE

The Personal Care portfolio of oral care products delivers active ingredients in toothpaste and mouthwashes; provides bioadhesive functionality for dentures; delivers flavor, texture and other functional properties; and provides product binding to ensure form and function throughout product lifecycle.

The Personal Care portfolio of hair care products includes advanced styling polymers, fixatives, conditioning polymers, emulsifiers, preservatives, rheology modifiers and biofunctional actives.

The Personal Care portfolio of ingredients and solutions for skin care, sun care, and cosmetics focuses on natural and sustainable solutions. Ashland’s Personal Care business includes biofunctional actives, preservatives, and specialty polymers to provide functionality such as water resistance and rheology. Ashland’s natural ingredients include a wide range of cellulose, guar, and cassia derivatives; unique active ingredients derived from botanical sources using exclusive Ashland technologies such as Zeta FractionTM and PSR technology; emollients based on natural chemistries; encapsulation technology derived from alginates; and efficacious preservative blends inspired by nature.

5


 

The Personal Care portfolio of products and technologies is used in many types of cleaning and fragrance applications, including fabric care, home care and dishwashing. Personal Care products are used in a variety of applications for viscosity enhancement, particle suspension, rheology modification, stabilization and fragrance enhancement.

Personal Care operates throughout the Americas, Europe and Asia Pacific. It has 15 manufacturing and lab facilities in nine countries which serve its various end markets and participates in one joint venture. It has manufacturing facilities and labs in Freetown, Massachusetts; Chatham, New Jersey; Ossining, New York; Merry Hill, North Carolina; Summerville, South Carolina; Kenedy, Texas; and Menomonee Falls, Wisconsin within the United States; Sao Paulo, Brazil; Shanghai, China; Sophia Antipolis, France; Hamburg, Germany; Mumbai, India; Mexico City, Mexico; Zwijndrecht, Netherlands and Poole, United Kingdom.

Personal Care markets and distributes its products in the Americas, Europe, the Middle East, Africa and Asia Pacific.

For fiscal 2023, the following Personal Care product categories were 10% or greater of Ashland’s total consolidated sales:

Product

% of Personal Care

% of Ashland total consolidated sales

Cellulosics

19%

37%

Polyvinylpyrrolidones (PVP)

21%

25%

SPECIALTY ADDITIVES

Specialty Additives offers industry-leading products, technologies and resources for solving formulation and product-performance challenges. Using synthetic and semisynthetic polymers derived from polyester and polyurethane-based adhesives, and plant and seed extract, Specialty Additives offers comprehensive and innovative solutions for industrial applications.

Key customers include manufacturers of paint, coatings and construction materials; packaging and converting companies; and oilfield service companies.

The areas of expertise include organic and synthetic chemistry, colloid science, rheology, structural analysis and microbiology.

The solutions provide an array of properties, including thickening and rheology control, binding power, film formation, conditioning and deposition, colloid stabilization and suspension.

Specialty Additives is composed of various end use markets. Many of the products of the end markets are produced in shared manufacturing facilities, to better manage capacity and achieve desired returns.

Specialty Additives provides products and services to over 30 industries. Ashland offers a broad spectrum of organo- and water-soluble polymers that are derived from both natural and synthetic resources. Product lines include derivatized cellulose polymers, synthetics, and vinyl pyrrolidone polymers that impart effective functionalities to serve a variety of industrial markets and specialized applications. Many of the products within Specialty Additives function as performance additives that deliver high levels of end-user value in formulated products. In other areas, such as plastics and textiles, Specialty Additives’ products function as a processing aid, improving the quality of end products and reducing manufacturing costs.

Specialty Additives is a recognized leader in rheology solutions for waterborne architectural paint and coatings. Products include hydroxyethylcellulose (HEC), which provides thickening and application properties for interior and exterior paints, and nonionic synthetic associative thickeners (NSATs), which are APEO-free liquid synthetics for high-performance paint and industrial coatings. The Specialty Additives market complements its rheology offering with a broad portfolio of performance foam-control agents, surfactants and wetting agents, dispersants and pH neutralizers.

Specialty Additives is a major producer and supplier of cellulose ethers and companion products for the construction industry. These products control properties such as water retention, open time, workability, adhesion, stabilization, pumping, sag resistance, rheology, strength, appearance and performance in dry-mortar formulations.

Specialty Additives is a leading global manufacturer of synthetic- and cellulosic-based products for drilling fluids, oil-well cement slurries, completion and workover fluids, fracturing fluids and production chemicals. Specialty Additives offers the oil and gas industry solutions for drilling, stimulation, completion, cementing and production applications.

6


 

Specialty Additives operates throughout the Americas, Europe and Asia Pacific. It has 11 manufacturing and lab facilities in nine countries which serve its various end markets. Specialty Additives has manufacturing facilities and labs in Parlin, New Jersey; and Hopewell, Virginia within the United States and Doel-Beveren, Belgium; Nanjing and Shanghai, China; Alizay, France; Dusseldorf, Germany; Mumbai, India; Zwijndrecht, the Netherlands; Singapore, Singapore; and Newton Aycliffe, United Kingdom.

Specialty Additives markets and distributes its products in the Americas, Europe, the Middle East, Africa and Asia Pacific.

For fiscal 2023, the following Specialty Additives products were 10% or greater of Ashland’s total consolidated sales:

Product

% of Specialty Additives sales

% of Ashland total consolidated sales

Cellulosics

66%

37%

Polyvinylpyrrolidones (PVP)

6%

25%

INTERMEDIATES

Intermediates is a leading producer of BDO and related derivatives, including n-methylpyrrolidone. These products are used as chemical intermediates in the production of engineering polymers and polyurethanes, and as specialty process solvents in a wide array of applications including electronics, pharmaceuticals, water filtration membranes and more. BDO is also supplied to Life Sciences, Personal Care and Specialty Additives for use as a raw material.

Key customers include Ashland’s Life Sciences, Personal Care and Specialty Additives segments, general industrial manufacturers, plastics and polymers producers, pharmaceutical companies, agricultural firms and producers of electronic components and systems.

Intermediates has a manufacturing facility in Lima, Ohio, while some derivatives are produced at Life Sciences facilities in Texas City, Texas and Calvert City, Kentucky. Intermediates markets and distributes its products in the Americas, Europe, and Asia Pacific.

MISCELLANEOUS

Environmental Matters

Ashland maintains a companywide environmental policy overseen by the Environmental, Health, Safety and Quality Committee of Ashland’s Board of Directors. Ashland’s Environmental, Health, Safety, Quality and Regulatory Affairs (EHSQ&RA) department has the responsibility to ensure that Ashland’s businesses worldwide maintain environmental compliance in accordance with applicable laws and regulations. This responsibility is carried out via training; widespread communication of EHSQ&RA policies; information and regulatory updates; formulation of relevant policies, procedures and work practices; design and implementation of EHSQ&RA management systems; internal auditing; monitoring of legislative and regulatory developments that may affect Ashland’s operations; assistance to the businesses in identifying compliance issues and opportunities for voluntary actions that go beyond compliance; and incident response planning and implementation.

Federal, state and local laws and regulations relating to the protection of the environment have a significant impact on how Ashland conducts its businesses. In addition, Ashland’s operations outside the United States are subject to the environmental laws of the countries in which they are located. These laws include regulation of air emissions and water discharges, waste handling, remediation and product inventory, registration and regulation. New laws and regulations may be enacted or adopted by various regulatory agencies globally. The costs of compliance with any new laws or regulations cannot be estimated until the manner in which they will be implemented has been more precisely defined.

At September 30, 2023, Ashland’s reserves for environmental remediation and related environmental litigation amounted to $214 million, reflecting Ashland’s estimates of the most likely costs that will be incurred over an extended period to remediate identified conditions for which the costs are reasonably estimable, without regard to any third-party recoveries. Engineering studies, historical experience and other factors are used to identify and evaluate remediation alternatives and their related costs in determining the estimated reserves for environmental remediation. Environmental remediation reserves are subject to

7


 

uncertainties that affect Ashland’s ability to estimate its share of the costs. Such uncertainties involve the nature and extent of contamination at each site and the extent of required cleanup efforts under existing environmental regulations. Although it is not possible to predict with certainty the ultimate costs of environmental remediation, Ashland currently estimates that the upper end of the reasonably possible range of future costs for identified sites could be as high as approximately $465 million. No individual remediation location is significant, as the largest reserve for any site is 21% of the remediation reserve. Ashland regularly adjusts its reserves as environmental remediation continues. Environmental remediation expense, net of insurance receivables, amounted to $59 million in 2023 compared to $66 million in 2022 and $51 million in 2021.

Product Control, Registration and Inventory - Many of Ashland’s products and operations are subject to chemical control laws of the countries in which they are located. These laws include regulation of chemical substances and inventories under the Toxic Substances Control Act (TSCA) in the United States and the Registration, Evaluation and Authorization of Chemicals (REACH) regulation in Europe as well as new cosmetic ingredients filings in China under the Cosmetics Supervision and Administration Regulation (CSAR). Under TSCA, REACH, and CSAR additional testing requirements, documentation, risk assessments and registrations are occurring and will continue to occur and may adversely affect Ashland’s costs of products produced in or imported into the European Union. Examples of other product control regulations include right to know laws under the Global Harmonized System (GHS) for hazard communication, regulation of chemicals used in the manufacture of pharmaceuticals and personal care products and that contact food under the Food, Drug and Cosmetics Act in the United States, the Framework Regulation in Europe and other product control requirements for chemical weapons, drug precursors and import/export. The Green Deal in the EU, specifically Chemicals Strategy for Sustainability, will require additional information to be developed on hazard communication and risk assessment of both chemical substances and finished products. New laws and regulations may be enacted or adopted by various regulatory agencies globally. The costs of compliance with any new laws or regulations cannot be estimated until the manner in which they will be implemented has been more precisely defined.

Remediation - Ashland currently operates, and in the past has operated, various facilities at which, during the normal course of business, releases of hazardous substances have occurred. Additionally, Ashland has known or alleged potential environmental liabilities at a number of third-party sites. Federal and state laws, including but not limited to the Resource Conservation and Recovery Act (RCRA), the Comprehensive Environmental Response, Compensation and Liability Act of 1980 (CERCLA) and various other remediation laws, require that contamination caused by hazardous substance releases be assessed and, if necessary, remediated to meet applicable standards. Some of these laws also provide for liability for related damage to natural resources, and claims for alleged property and personal injury damage which can also arise related to contaminated sites. Laws in other jurisdictions in which Ashland operates require that contamination caused by such releases at these sites be assessed and, if necessary, remediated to meet applicable standards.

Air - In the United States, the Clean Air Act (CAA) imposes stringent limits on facility air emissions, establishes a federally mandated operating permit program, allows for civil and criminal enforcement actions and sets limits on the volatile or toxic content of many types of industrial materials and consumer products. The CAA establishes national ambient air quality standards (NAAQS) with attainment deadlines and control requirements based on the severity of air pollution in a given geographical area. Various state clean air acts implement, complement and, in many instances, add to the requirements of the federal CAA. The requirements of the CAA and its state counterparts have a significant impact on the daily operation of Ashland’s businesses and, in many cases, on product formulation and other long-term business decisions. Other countries where Ashland operates also have laws and regulations relating to air quality. Ashland’s businesses maintain numerous permits and emission control devices pursuant to these clean air laws.

The United States Environmental Protection Agency (USEPA) has increased its frequency in reviewing the NAAQS. The USEPA has stringent standards for particulate matter, ozone and sulfur dioxide. Throughout 2022 and 2023, state and local agencies continued to implement options for meeting the newest standards. Particulate matter strategies include dust control measures for construction sites and reductions in emission rates allowed for industrial operations. Options for ozone include emission controls for certain types of sources, reduced limits on the volatile organic compound content of industrial materials and consumer products, and requirements on the transportation sector. Most options for sulfur dioxide focus on coal and diesel fuel combustion sources. It is not possible at this time to estimate the potential financial impact that these newest standards may

8


 

have on Ashland’s operations or products. Ashland will continue to monitor and evaluate these standards to meet these and all air quality requirements.

Solid Waste - Ashland’s businesses are subject to various laws relating to and establishing standards for the management of hazardous and solid waste. In the United States, Ashland’s facilities are subject to RCRA and its regulations governing generators of hazardous waste. Ashland has implemented systems to oversee compliance with the RCRA regulations. In addition to regulating current waste disposal practices, RCRA also addresses the environmental effects of certain past waste disposal operations, the recycling of wastes and the storage of regulated substances in underground tanks. Ashland has the remediation liability for certain facilities subject to these regulations. Other countries where Ashland operates also have laws and regulations relating to hazardous and solid waste, and Ashland has systems in place to oversee compliance.

Water - Ashland’s businesses maintain numerous discharge permits. In the United States, such permits may be required by the National Pollutant Discharge Elimination System of the Clean Water Act and similar state programs. Other countries have similar laws and regulations requiring permits and controls relating to water discharge.

Climate Change and Related Regulatory Developments - Ashland has been collecting energy use data and calculating greenhouse gas (GHG) emissions for many years. Ashland evaluates the physical and transitional risks and opportunities from both climate change and the anticipated GHG regulations to facilities, products and other business interests, as well as the strategies commonly considered by the industrial sector to reduce the potential impact of these risks. These risks are generally grouped as impacts from legislative, regulatory and international developments, impacts from business and investment trends and impacts to Company assets from the physical effects of climate change. North American, European and other regional regulatory developments (most notably the pending SEC and approved Corporate Sustainability Reporting Directive (CSRD) climate disclosure regulations) are monitored continuously for material impacts to Ashland’s operations, and some facilities and subsidiaries are subject to promulgated rules. Proposed and pending climate legislation is monitored for impact and Ashland is taking steps to strengthen climate reporting to meet anticipated disclosure requirements. Other requirements requiring additional product level climate disclosures or supply chain transparency are also approved and in draft or finalized status and could impact the requirements for disclosure and restrictions on sourcing of raw materials. Regulations such as the PFAS restrictions and Microplastics ban in the EU have potential business interruption impacts where they limit the type and availability of raw materials that may be used.

Business and investment trends are expected to drive an increase in the demand for products that improve energy efficiency, reduce energy use and increase the use of renewable resources. At this time, Ashland cannot estimate the impact of this expected demand increase to its businesses. Physical effects from climate change have the potential to affect Ashland’s assets in areas prone to sea level rise or extreme weather events much as they do the general public and other businesses. Due to the uncertainty of these matters, Ashland cannot estimate the impact at this time of GHG-related developments on its operations or financial condition.

Competition

Ashland competes in the highly fragmented additives and specialty ingredients industries. The participants in these industries offer a varied and broad array of product lines designed to meet specific customer requirements. Participants compete with service and product offerings on a global, regional and/or local level subject to the nature of the businesses and products, as well as the end-markets and customers served. Competition is based on several key criteria, including product performance and quality, product price, product availability and security of supply, responsiveness of product development in cooperation with customers, customer service, industry knowledge and technical capability. Certain key competitors are significantly larger than Ashland and have greater financial resources, leading to greater operating and financial flexibility. The industry has become increasingly global as participants have focused on establishing and maintaining leadership positions outside of their home markets. Many of these segments’ product lines face domestic and international competition, due to industry consolidation, pricing pressures and competing technologies. To improve its competitive position, as Ashland narrows its focus, the Company is building and leveraging the Ashland corporate brand as a differentiator to create value and better communicate the capabilities, promise and scale of the Company, making it easier to introduce new product lines and applications.

9


 

Intellectual Property

Ashland has a broad intellectual property portfolio which is an important component of its business. Ashland relies on patents, trade secrets, formulae and know-how to protect and differentiate its products and technologies. In addition, the reportable segments own valuable trademarks which identify and differentiate its products from its competitors. Ashland also uses licensed intellectual property rights from third-parties.

Raw Materials and Energy

Ashland purchases its raw materials from multiple sources of supply in the United States and other countries. Raw material supplies were available in quantities sufficient to meet demand in fiscal 2023, which was a significant improvement over fiscal 2022 when raw and packaging materials were globally constrained. Similarly, energy costs, which are a significant component of production costs, stabilized in fiscal 2023 after significant volatility in 2022.

Research and Development

Ashland’s program of research and development is focused on defining the needs of the marketplace and framing those needs into technology platforms. Ashland has the capability to develop and deliver the intellectual property required to grow and protect those platforms. Ashland is focused on developing new chemistries, market-changing technologies and customer driven solutions at numerous technology centers located in the Americas, Europe and the Asia Pacific regions.

Seasonality

Ashland’s business may vary due to seasonality. Ashland’s business units typically experience stronger demand during warmer weather months.

Human Capital

Employee Health and Safety - Cultivating a safety culture is intentional at Ashland and is best shown by its commitment to a Zero Incident Culture (ZIC). ZIC begins with the vision, values, beliefs, and actions of Ashland’s leaders demonstrating that zero incidents is possible. It means developing processes where compliance is the minimum expectation, allowing employees to proactively manage safety above compliance on the journey to zero.

As an indication of its commitment to Responsible Care, Ashland obtained a third-party certification to RC14001, which includes the internationally recognized ISO 14001 certification and adds additional health, safety, security, and chemical industry requirements. Currently, Ashland has 24 international sites participating on a group RC14001 certification. Also, as part of its commitment to health and safety, 16 of the Company's sites have obtained an additional ISO 45001 certification, an international health and safety management system.

As part of ZIC, the Company strives every day to achieve zero incidents. Ashland continues to make good progress on its journey. For the year ended September 30, 2023, the Company had a Total Preventable Recordable Rate (TPRR) of 0.39 compared to 0.58 for the year ended September 30, 2022.

Ashland has implemented several tools for communicating lessons learned from injuries, process safety incidents, and environmental releases. Immediately following an event, flash reports are developed and shared to communicate key lessons learned across the Company with a review call within 48 hours with EHS and Operations Leadership. Additionally, incidents and root causes/corrective and preventive actions are reviewed monthly with Company leadership and EHS leaders globally to discuss areas for improvement and highlight the importance of identifying and addressing management system errors.

Ashland has implemented the “Good Catch” Program aimed at identifying underlying unsafe conditions or behaviors that could lead to an undesirable outcome. Employees are encouraged to report good catches that fall into one of three categories – substandard conditions, near misses, and suggestions. These are tracked with the goal of continuing to increase overall reporting of identified good catches year to year.

Environmental - Ashland has a conscious and proactive mindset for sustainability and has established a renewable annual trust for ongoing and future environmental remediation and related litigation cash outlays. The initiative follows Ashland's announcement in February 2021 to align its operations with the ambitious aim of the Paris Climate Accord to limit global

10


 

temperature rise to 1.5°C above preindustrial levels. At that time, Ashland also became a signatory to the United Nations Global Compact and is making the United Nations principles part of the Company's business strategy, culture, and day-to-day operations. Ashland has targets to reduce its environmental footprint (including energy usage, GHG emissions, and hazardous waste generation). These targets and progress towards meeting them can be found on: https://www.ashland.com/esg/esg-overview, which is not incorporated by reference into the Annual Report on Form 10-K.

Human Capital Management - Ashland is committed to continuously evaluating and strengthening the growth-minded and innovative culture by attracting and developing exceptional global talent, supporting employees’ physical, emotional, and financial well-being, and recognizing and rewarding performance. To achieve the highest return, Ashland is building an inclusive and high-integrity organization where everyone belongs, feels inspired to excel, and does the right thing.

As of September 30, 2023, Ashland had approximately 3,800 employees who thrive on developing practical, innovative, and simple solutions to complex problems for customers in more than 100 countries. The employees’ global demographics consist of approximately 68% male employees and approximately 31% female employees, and in the U.S., approximately 26% of its employees self-identify as ethnically diverse.

Ashland's global footprint is geographically located as follows:

https://cdn.kscope.io/83d9d1eccb376045c3d3f02f9b457cde-img138869020_0.jpg 

Competitive Pay and Benefits - Ashland is committed to paying its employees in a fair and equitable manner, regardless of race or gender, and has implemented global total rewards tools to promote equitable remuneration. The Company provides a total compensation package that is designed to be competitive with the markets in which it competes for talent. Ashland believes employees should be compensated equitably based on performance, skills, and experience.

Ashland reviews pay equity annually in conjunction with its annual performance review, merit, bonus and promotion processes. The Company annually completes an in-depth analysis of its pay equity globally using a number of factors to determine if a pay gap exists based on any protected factors (gender, age, race, veteran status). Overall findings continue to be encouraging, identifying only a few employees annually that had a disparity in pay requiring further analysis and corrective action. Ashland reviews each process annually to ensure that its policies, procedures, and training continue to provide pay equity within the Company.

The Company’s compensation programs are globally aligned, and, where possible, its total rewards plans include base salary, short and long-term incentives, benefits, financial, and special recognition programs. The Company routinely reviews its total rewards practices in the markets in which it operates to ensure its plans allow for the recruitment and retention of the talent it needs to be successful.

11


 

Ashland also offers a competitive global benefits program to support employees through all life stages. The following benefit plans are available to employees depending on local markets in which the Company operates that include plan specific features such as on-site and on-demand resources:

Health care benefits including medical, prescription, dental and/or vision
Wellness initiatives:
o
Global EAP (employee assistance program)
o
Flu vaccination resources
Paid time off
Voluntary benefits
Life and accident coverage
Disability coverage
Retirement plans
Tuition reimbursement
Business travel accident

Inclusion and Diversity - In 2023, Ashland progressed its global inclusion and diversity strategy focused on belonging, accountability, community engagement, recruitment, and internal mobility. These priorities serve as the basis of the global and local objectives and initiatives that advance Ashland's collective progress towards equity. The company and its leadership team are committed to creating a collaborative environment that leverages the talents of a diverse global workforce to drive sustainable growth and innovation that creates value for its shareholders, customers, employees, and the communities in which it operates.

Ashland’s commitment to inclusion and diversity starts at the top with its Board and its executive leadership. The Company’s board of directors is comprised of individuals with diverse experience and credentials, selected for their business acumen and ability to challenge and add value to management. These directors have held significant leadership positions and bring a depth of experience across a wide variety of industries, providing the Company with unique insights and fresh perspectives. The demographics of the Company’s board of directors is 60% diverse, including females and ethnically diverse males.

The Company’s management is led by its President and Chief Executive Officer and the other members of the Executive Committee (“EC”). The demographics of the EC include 20% women and 50% males who identify as ethnically diverse individuals. The chart below shows the Company’s global gender diversity and US ethnic and gender diversity progress over the past three years and the Company’s future global gender diversity and US ethnic and gender diversity commitments.

https://cdn.kscope.io/83d9d1eccb376045c3d3f02f9b457cde-img138869020_1.jpg 

 

 

12


 

Talent Management - Ashland is dedicated to creating a purpose-driven people ecosystem that enables personal and professional growth at every level while minimizing risk to the business. The Company deploys a disciplined annual talent review and succession process to identify and develop a leadership pipeline that accelerates business results, promotes internal mobility, and minimizes attrition. The talent management process includes a performance management process that seeks to provide employees with on-going feedback to enhance their performance in support of the Company’s business objectives. As part of Ashland's commitment to professional development, it offers associate’s and bachelor’s undergraduate, graduate, and PhD tuition assistance to eligible employees, along with ongoing technical and professional development.

In 2023, the Company elevated the skillset of its leaders to support the career development of their employees and provided continued learning on inclusion and allyship. Ashland conducted its second annual global Culture Survey, with 79% response rate, which provided valuable insight to prioritize investments in the tools, resources, and processes that will make a positive impact on employee’s well-being, engagement, and career growth. Ashland remains committed to continuously listening and evolving its people practices to align with and drive the Company’s purpose and business success.

Forward-Looking Statements

This Annual Report on Form 10-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These forward-looking statements are not historical facts and generally are identified by words such as “anticipates,” “believes,” “estimates,” “expects,” “is likely,” “predicts,” “projects,” “forecasts,” “objectives,” “may,” “will,” “should,” “plans,” and “intends” and the negative of these words or other comparable terminology. Although Ashland believes that its expectations are based on reasonable assumptions, such expectations are subject to risks and uncertainties that are difficult to predict and may be beyond Ashland’s control. As a result, Ashland cannot assure that the expectations contained in such statements will be achieved. Important factors that could cause actual results to differ materially from those contained in such statements are discussed under “Use of estimates, risks and uncertainties” in Note A of Notes to Consolidated Financial Statements in this Annual Report on Form 10-K. For a discussion of other factors and risks that could affect Ashland’s expectations and operations, see “Item 1A. Risk Factors” in this Annual Report on Form 10-K.

 

ITEM 1A. RISK FACTORS

The following discussion of “risk factors” identifies the most significant factors that may adversely affect Ashland’s business, operations, financial position or future financial performance. This information should be read in conjunction with Management’s Discussion and Analysis and the consolidated financial statements and related notes incorporated by reference into this Annual Report on Form 10-K. The following discussion of risks is designed to highlight what Ashland believes are important factors to consider when evaluating its expectations. These factors could cause future results to differ from those in forward-looking statements and from historical trends.

Risks Related to the Company’s Business Operations, Financial Performance and Growth

Ashland has set aggressive growth goals for its businesses, including increasing sales, cash flow and margins, in order to achieve its long-term strategic objectives and improve shareholder value. Ashland’s successful execution of its growth strategies and business plans to facilitate that growth involves a number of risks.

Ashland’s failure to fully achieve one or more of its aggressive growth goals or meet its long-term objectives, could negatively impact Ashland’s potential value and its businesses. One of the most important risks is that Ashland might fail to adequately execute its business and growth plans, by optimizing the efficient use of its physical and intangible assets. Aspects of that risk include changes to global economic environment, changes to the competitive landscape, attraction and retention of skilled employees, the potential failure of product innovation plans, failure to comply with existing or new regulatory schemes, failure to maintain a competitive cost structure and other risks outlined in greater detail in this Item 1A. In addition, Ashland, as part of its growth goals, continuously evaluates acquisition candidates. If Ashland is unable to successfully identify and integrate acquired businesses, Ashland could fail to achieve any expected increases in sales and operating results, which could have a material adverse effect on Ashland’s financial results. Ashland’s ability to achieve the anticipated financial benefits from any acquisition transactions may not be realized due to any number of factors, including, but not limited to, unsuccessful integration

13


 

efforts, unexpected or underestimated liabilities or increased costs, fees, expenses and charges related to such transactions. Such adverse events could result in a decrease in the estimated fair value of goodwill or other intangible assets established as a result of such transactions, triggering an impairment. These and other factors could have a material adverse effect on our financial condition and results of operations.

Business disruptions from natural, operational and other catastrophic risks could seriously harm Ashland’s operations and financial performance. In addition, a catastrophic event at one of Ashland’s facilities or involving its products or employees could lead to liabilities that could further impair its operations and financial performance.

Business disruptions, including those related to operating hazards inherent with the production of chemicals, natural disasters, severe weather conditions, supply or logistics disruptions, increasing costs for energy, temporary plant and/or power outages, information technology systems and network disruptions, cyber-security breach, terrorist attacks, armed conflict, war, public health crisis (such as the COVID-19 pandemic), fires, floods or other catastrophic events, could seriously harm Ashland’s operations, as well as the operations of its customers and suppliers, and may adversely impact Ashland’s financial performance. Although it is impossible to predict the occurrence or consequences of any such events, they could result in reduced demand for Ashland’s products, make it difficult or impossible for Ashland to manufacture its products or deliver products to its customers or to receive raw materials from suppliers, or create delays and inefficiencies in the supply chain. In addition to leading to a serious disruption of Ashland’s businesses, a catastrophic event at one of our facilities or involving our products or employees could lead to substantial legal liability to or claims by parties allegedly harmed by the event.

Furthermore, because catastrophic events are inherently uncertain, Ashland's business continuity plans may not address every potential scenario and may not fully protect it from all such events. In addition, insurance maintained by Ashland to protect against property damage, loss of business and other related consequences resulting from catastrophic events is subject to various deductibles and coverage limitations, depending on the nature of the risk insured. This insurance may not be sufficient to cover all of Ashland’s damages or damages to others in the event of a catastrophe. In addition, insurance related to these types of risks may not be available now or, if available, may not be available in the future at commercially reasonable rates.

 

Climate change and resource impacts including supply chain disruptions, operational impacts, and geopolitical events may impact Ashland's business operations.

Ashland sources a large number of raw materials from third party suppliers globally. These products include both natural and synthetic materials derived from plants, animal products, organic and petroleum based raw materials. Disruptions to the global supply chain due to climate related impacts or geopolitical events are possible and exist as external risk factors that the Company can respond to but not control. These events could limit the supply of key raw materials to the Company, or could have significant impacts to pricing. Ashland works with multiple raw material suppliers to mitigate lack of availability from a single supplier, however in some cases products with limited numbers of suppliers may become difficult to obtain.

Ashland has manufacturing operations in areas vulnerable to coastal storms which may increase in magnitude and impact due to climate change. Ashland continues to implement response and resilience measures such as storm hardening and business continuity planning, however increasingly large and unprecedented weather events may pose a risk to business operations in vulnerable areas. Storms could cause business interruptions, incur additional restoration costs, and impact product availability and pricing.

Consumer preference is increasingly impacted by awareness of and a response to climate change. Consumers are increasingly demanding responsibly sourced and manufactured products. An inability to respond to consumer demands through environmental, social and governance (ESG) innovation could lead to a loss of sales to competitors providing more sustainable product offerings.

Energy availability and pricing has been impacted by geopolitical events and may be impacted by climate related legislation and regulations. As climate legislation increases in many countries, the availability of conventional and nonrenewable energy may be increasingly limited and prices may continue to increase. Where demand exceeds energy capacity, energy disruptions such as brown out or black out events are possible, leading to business interruption and quality/operational impacts. Failure to respond to or mitigate this risk could lead to increased cost and business impacts.

14


 

Globally, the availability of fresh, potable water is a growing concern, where water withdrawal can exceed the rates of surface and groundwater replenishment in critical basins, rivers, or other bodies of water. This concern continues to increase for Ashland and for the global supply chain where fresh water is a key resource for manufacturing operations. Failure to respond to this risk could lead to business interruptions and impact the availability and pricing of product.

Ashland sources several key natural raw materials that contain processed timber, palm, soy, and other harvested or farmed raw materials. Deforestation is an increasing concern where the irresponsible harvest of these raw materials can lead to loss of critical forests and habitats. Ashland has engaged in several supply chain certifications in an effort to source sustainable raw materials; however, the availability of these raw materials may be limited in the future. Additional sourcing of these materials is under increasing scrutiny due to deforestation. Failure to source responsibly and respond to or mitigate the risk could lead to business impacts and increased cost.

Ashland’s customers could change their products in a way that reduces the demand for Ashland’s products.

Ashland produces and sells specialty materials that are used by its customers for a broad range of applications. Many of these Ashland materials become part of end products that are sold to consumers. Changes in consumer preferences and demands can lead to certain Ashland customers making changes to their products. In other instances, Ashland’s customers may change their products or production techniques to take advantage of newer technologies, alternative chemistries, more effective formulations, or improved processes, or in response to various market, technical or regulatory changes.

Such changes in Ashland’s customers’ products or production techniques may cause these customers to reduce consumption of Ashland’s products or eliminate their need entirely. Ashland may not be able to supply products that meet the customers’ new requirements. Such lost sales opportunities may not be replaced by those offering equal revenue potential or margin. It is important for Ashland to continue developing new products, and new applications of existing products to replace such lost business. Otherwise, Ashland faces the risk of a loss of market share, margins and cash flow if it is unable to manage a potential change in the demands of its products.

Ashland’s substantial global operations subject it to risks of doing business in foreign countries, which could adversely affect its business, financial condition and results of operations.

Greater than half of Ashland’s net sales for fiscal 2023 were to customers outside of North America. Ashland expects sales from international markets to continue to represent an even larger portion of the Company’s sales in the future. Also, a significant portion of Ashland’s manufacturing capacity is located outside of the United States. Accordingly, Ashland’s business is subject to risks related to the differing legal, political, cultural, social and regulatory requirements and economic conditions of many jurisdictions.

The global nature of Ashland’s business presents difficulties in hiring and maintaining a workforce in certain countries. Fluctuations in exchange rates may affect product demand and may adversely affect the profitability in U.S. dollars of products and services provided in foreign countries. In addition, foreign countries may impose additional withholding taxes or otherwise tax Ashland’s foreign income, or adopt other restrictions on foreign trade or investment, including currency exchange controls. The imposition of new tariffs or trade quotas, or an impairment of existing trade agreements is also a risk that could impair Ashland’s financial performance.

Certain legal and political risks are also inherent in the operation of a company with Ashland’s global scope. Ashland’s ability to do business and execute its growth strategies could be adversely affected by legal and political changes or other changes to trade policy and trade relationships. Ashland could also be impacted negatively if the ongoing trade disputes between the United States and China, or those between the United States and the E.U. were to worsen. In addition, it may be more difficult for Ashland to enforce its agreements or collect receivables through foreign legal systems. There is a risk that foreign governments may nationalize private enterprises in certain countries where Ashland operates. In certain countries or regions, terrorist activities and the response to such activities may threaten Ashland’s operations more than those in the United States. In Europe, the effect of economic sanctions imposed on Russia and/or Russia’s reaction to the sanctions could adversely impact Ashland’s performance and results of operations. The risks associated with localized or regional armed conflict in many parts of the world remain high and could disrupt and/or adversely impact Ashland’s businesses. Social and cultural norms in certain countries may not support compliance with Ashland’s corporate policies including those that require compliance with substantive laws and

15


 

regulations. Also, changes in general economic and political conditions in countries where Ashland operates, particularly in Europe, the Middle East and emerging markets, are a risk to Ashland’s financial performance.

As Ashland continues to operate its business globally, its success will depend, in part, on its ability to anticipate and effectively manage these and other related risks. There can be no assurance that the consequences of these and other factors relating to its multinational operations will not have an adverse effect on Ashland’s business, financial condition or results of operations.

Adverse developments in the global economy and potential disruptions of financial markets could negatively impact Ashland’s customers and suppliers, and therefore have a negative impact on Ashland’s results of operations.

A global or regional economic downturn may reduce customer demand or inhibit Ashland’s ability to produce and sell products. Ashland’s business and operating results are sensitive to global and regional economic downturns, credit market tightness, declining consumer and business confidence, fluctuating commodity prices, volatile exchange rates, inflation or changes in interest rates, sovereign debt defaults and other challenges, including those related to international sanctions and acts of aggression or threatened aggression that can affect the global economy. In the event of adverse developments or stagnation in the economy or financial markets, Ashland’s customers may experience deterioration of their businesses, reduced demand for their products, cash flow shortages and difficulty obtaining financing. As a result, existing or potential customers might delay or cancel plans to purchase products, which includes customer destocking of their own inventories, and may not be able to fulfill their obligations to Ashland in a timely fashion. Further, suppliers may experience similar conditions, which could impact their ability to fulfill their obligations to Ashland. A weakening or reversal of the current economic conditions in the global economy or a substantial part of it could negatively impact Ashland’s business, results of operations, financial condition and ability to grow.

Ashland’s substantial indebtedness may adversely affect its business, results of operations and financial condition.

Ashland maintains a substantial amount of debt. Ashland’s substantial indebtedness could adversely affect its business, results of operations and financial condition by, among other things:

requiring Ashland to dedicate a substantial portion of its cash flow from operations to pay principal and interest on its debt, which would reduce the availability of Ashland’s cash flow to fund working capital, capital expenditures, acquisitions, execution of its growth strategy and other general corporate purposes;
limiting Ashland’s ability to borrow additional amounts to fund working capital, capital expenditures, acquisitions, debt service requirements, execution of its growth strategy and other purposes;
making Ashland more vulnerable to adverse changes in general economic, industry and regulatory conditions and in its business by limiting Ashland’s flexibility in planning for, and making it more difficult for Ashland to react quickly to, changing conditions;
placing Ashland at a competitive disadvantage compared with those of its competitors that have less debt and lower debt service requirements;
making Ashland more vulnerable to increases in interest rates if debt is refinanced; and
making it more difficult for Ashland to satisfy its financial obligations.

In addition, Ashland may not be able to generate sufficient cash flow from its operations to repay its indebtedness when it becomes due and to meet its other cash needs. If Ashland is not able to pay its debts as they become due, it could be in default under its credit facility or other indebtedness. Ashland might also be required to pursue one or more alternative strategies to repay indebtedness, such as selling assets, refinancing or restructuring its indebtedness or selling additional debt or equity securities. Ashland may not be able to refinance its debt or sell additional debt or equity securities or its assets on favorable terms, if at all, and if Ashland must sell its assets, it may negatively affect its ability to generate revenues.

16


 

Risks Related to Competition

Failure to develop and market new products and production technologies could impact Ashland’s competitive position and have an adverse effect on its businesses and results of operations.

The specialty additives and materials industry is subject to periodic technological change and ongoing product improvements. In order to maintain margins and remain competitive, Ashland must successfully develop and introduce new products or improvements that appeal to its customers and ultimately to global consumers. Ashland plans to grow earnings, in part, by focusing on developing markets and solutions to meet increasing demand in those markets, including demand for personal care and pharmaceutical products which are subject to lengthy regulatory approval processes. The fast change in Ashland’s industry and those of its customers necessitates that Ashland continue the development of new technologies to replace older technologies whose demand or market position may be fading. Ashland’s efforts to respond to changes in customer demand in a timely and cost-efficient manner to drive growth could be adversely affected by difficulties or delays in product development, including the inability to identify viable new products, successfully complete research and development, obtain regulatory approvals, obtain intellectual property protection or gain market acceptance of new products. Due to the lengthy development process, technological challenges and intense competition, there can be no assurance that any of the products Ashland is currently developing, or could develop in the future, will achieve substantial commercial success.

The competitive nature of Ashland’s markets may delay or prevent Ashland from passing increases in raw materials or energy costs on to its customers. In addition, certain of Ashland’s suppliers may be unable to deliver products or raw materials or fulfill contractual requirements. The occurrence of either event could adversely affect Ashland’s results of operations.

Rising and volatile raw material prices, especially those of hydrocarbon derivatives, cotton linters or wood pulp, may negatively impact Ashland’s costs, results of operations and the valuation of its inventory. Similarly, energy costs are a significant component of certain of Ashland’s product costs. Ashland is not always able to raise prices in response to such increased costs, and its ability to pass on the costs of such price increases is dependent upon market conditions. Likewise, reductions in the valuation of Ashland’s inventory due to market volatility may not be recovered and could result in losses.

Ashland purchases certain products and raw materials from suppliers, often pursuant to written supply contracts. If those suppliers are unable to meet Ashland’s orders in a timely manner or choose to terminate or not fulfill contractual arrangements, Ashland may not be able to make alternative supply arrangements. Also, domestic and global government regulations related to the manufacture, transport or import of certain raw materials may impede Ashland’s ability to obtain those raw materials on commercially reasonable terms. Certain Ashland businesses rely on agricultural output of clary sage, aloe, guar, and cotton linters, and the availability of these materials can be severely impacted by crop yields, weather events, and other factors. If Ashland is unable to obtain and retain qualified suppliers under commercially acceptable terms, its ability to manufacture and deliver products in a timely, competitive and profitable manner or grow its business successfully could be adversely affected.

 

Ashland faces competition from other companies, which places downward pressure on prices and margins and may adversely affect Ashland’s businesses and results of operations.

Ashland operates in highly competitive markets, competing against a number of domestic and foreign companies. Competition is based on several key criteria, including product performance and quality, product price, product availability and security of supply, responsiveness of product development in cooperation with customers and customer service, as well as the ability to bring innovative products or services to the marketplace. Certain key competitors are significantly larger than Ashland and have greater financial resources, leading to greater operating and financial flexibility. As a result, these competitors may be better able to withstand changes in conditions within the relevant industry, changes in the prices of raw materials and energy and changes in general economic conditions. In addition, competitors’ pricing decisions could compel Ashland to decrease its prices, which could negatively affect its margins and profitability. Additional competition in markets served by Ashland could adversely affect margins and profitability and could lead to a reduction in market share. Also, Ashland competes in certain markets that are declining and has targeted other markets for growth opportunities. Competitive and pricing pressures could also impact Ashland’s production volumes, which can in turn reduce cost efficiency. If Ashland’s strategies for dealing with declining markets and leveraging opportunity markets are not successful, its businesses and results of operations could be negatively affected.

17


 

Risks Related to Human Capital

Ashland’s success depends upon its ability to attract and retain key employees and the identification and development of talent to succeed senior management.

Ashland’s success depends on its ability to attract and retain key personnel, and Ashland relies heavily on its management team. Therefore, Ashland’s future success depends, in part, on its ability to identify and develop talent to succeed its senior management and other key positions throughout the organization. If Ashland fails to identify and develop successors, the Company is at risk of being harmed by the departures of these key employees. The inability to recruit and retain key personnel or the unexpected loss, voluntarily or otherwise, of key personnel may adversely affect Ashland’s operations. Monitoring and preventing unwanted employee turnover in positions that require certain technical expertise or those that have been identified as successors to senior management will be critical to Ashland’s future success.

Risks Related to Intellectual Property and Cyber Threats

Ashland uses information technology (IT) systems to conduct business and these IT systems are at risk of potential disruption and cyber security threats.

Ashland’s businesses rely on IT systems to operate efficiently and in some cases, to operate at all. Ashland employs third parties to manage and maintain a significant portion of its IT systems, including, but not limited to data centers, IT infrastructure, network, client support and end user services, as well as the functions of backing up and securing those systems. A partial or complete failure of Ashland’s IT systems or those of our third parties managing, providing or servicing them for any amount of time more than several hours could result in significant business disruption causing harm to Ashland’s reputation, results of operations or financial condition. In addition, the nature of our businesses, the markets we serve, and the extensive geographic profile of our operations make Ashland a target of cyber security threats. Despite steps Ashland takes to mitigate or eliminate them, cyber security threats in general are increasing and becoming more advanced and could occur as a result of the activity of hackers, employee error or employee misconduct. A breach of our IT systems could lead to the loss and destruction of trade secrets, confidential information, proprietary data, intellectual property, customer and supplier data, and employee personal information. A breach could also expose us to customer litigation, regulatory actions and costs related to the reporting and handling of such a violation or breach, all of which could disrupt our business operations and could adversely affect Ashland’s relationships with business partners, harm our brands, reputation, and financial results.

Ashland may not be able to effectively protect or enforce its intellectual property rights.

Ashland relies on the patent, trademark, trade secret and copyright laws of the United States and other countries to protect its intellectual property rights. The laws of some countries may not protect Ashland’s intellectual property rights to the same extent as the laws of the United States. Failure of foreign countries to have laws to protect Ashland’s intellectual property rights or an inability to effectively enforce such rights in foreign countries could result in the loss of valuable proprietary information, which could have an adverse effect on Ashland’s business and results of operations.

Even in circumstances where Ashland has a patent on certain technologies, such patents may not provide meaningful protection against competitors or against competing technologies. In addition, any patent applications submitted by Ashland may not result in an issued patent. There can be no assurance that Ashland’s intellectual property rights will not be challenged, invalidated, circumvented or rendered unenforceable. Ashland could also face claims from third parties alleging that Ashland’s products or processes infringe on their proprietary rights. If Ashland is found liable for infringement, it could be responsible for significant damages, prohibited from using certain products or processes or required to modify certain products and processes. Any such infringement liability could adversely affect Ashland’s product and service offerings, profitability and results of operations.

Ashland also has substantial intellectual property associated with its know-how and trade secrets that are not protected by patent or copyright laws. Ashland protects these rights by entering into confidentiality and non-disclosure agreements with most of its employees and with third parties. There can be no assurance that such agreements will not be breached or that Ashland will be able to effectively enforce them. In addition, Ashland’s trade secrets and know-how may be improperly obtained by other

18


 

means, such as a breach of Ashland’s information technologies security systems or direct theft. Any unauthorized disclosure of any of Ashland’s material know-how or trade secrets could adversely affect Ashland’s business and results of operations.

Risks Related to Legal and Regulatory Compliance and Litigation

Ashland’s business exposes it to potential product liability claims and recalls, which could adversely affect its financial condition and performance.

The development, manufacture and sale of specialty materials and other products by Ashland, including products produced for the food, beverage, personal care, pharmaceutical and nutritional supplement industries, involve an inherent risk of exposure to product liability claims, product recalls, product seizures and related adverse publicity. Ashland also produces products that are subject to rigorous specifications and quality standards, with an expectation from its customers around these strict requirements. A product liability claim, recall or judgment against Ashland, or a customer complaint on product specifications, could also result in substantial and unexpected expenditures, affect consumer or customer confidence in its products, and divert management’s attention from other responsibilities. Although Ashland maintains product liability insurance, there can be no assurance that this type or level of coverage is adequate or that Ashland will be able to continue to maintain its existing insurance or obtain comparable insurance at a reasonable cost, if at all. A product recall or a partially or completely uninsured product liability judgment against Ashland could have a material adverse effect on its reputation, results of operations and financial condition.

Ashland has incurred, and will continue to incur, substantial costs as a result of environmental, health and safety, and hazardous substances liabilities and related compliance requirements. These costs could adversely impact Ashland’s cash flow, and, to the extent they exceed Ashland’s established reserves for these liabilities, its results of operations.

Ashland is subject to extensive federal, state, local and foreign laws, regulations, rules and ordinances relating to pollution, protection of the environment and human health and safety, and the generation, storage, handling, treatment, disposal and remediation of hazardous substances and waste materials. Ashland has incurred, and will continue to incur, significant costs and capital expenditures to comply with these laws and regulations.

Environmental, health and safety regulations change over time, and such regulations and their enforcement have tended to become more stringent. Accordingly, changes in environmental, health and safety laws and regulations and the enforcement of such laws and regulations could interrupt Ashland’s operations, require modifications to its facilities or cause Ashland to incur significant liabilities, costs or losses that could adversely affect its profitability. Actual or alleged violations of environmental, health or safety laws and regulations could result in restrictions or prohibitions on plant operations as well as substantial damages, penalties, fines, civil or criminal sanctions and remediation costs. In addition, under some environmental laws, Ashland may be strictly liable and/or jointly and severally liable for environmental damages and penalties.

Ashland is also subject to various federal, state, local and foreign environmental laws and regulations that require environmental assessment or remediation efforts (collectively, environmental remediation) at multiple locations. Ashland uses engineering studies, historical experience and other factors to identify and evaluate remediation alternatives and their related costs in determining the estimated reserves for environmental remediation. Environmental remediation reserves are subject to numerous inherent uncertainties that affect Ashland’s ability to estimate its share of the applicable costs. Such uncertainties involve the nature and extent of contamination at each site and the extent of required cleanup efforts under existing environmental regulations, with varying costs of alternate cleanup methods. There may also be situations in which certain environmental liabilities are not known to Ashland or are not probable and estimable. As a result, Ashland’s actual costs for environmental remediation could adversely affect Ashland’s cash flow and, to the extent costs exceed established reserves for those liabilities, its results of operations.

Ashland is responsible for, and has financial exposure to, liabilities from pending and threatened claims, including those alleging personal injury caused by exposure to asbestos, which could adversely impact Ashland’s results of operations and cash flow.

There are various claims, lawsuits and administrative proceedings pending or threatened, including those alleging personal injury caused by exposure to asbestos, against Ashland and its current and former subsidiaries. Such actions are with respect to

19


 

commercial matters, product liability, toxic tort liability and other matters that seek remedies or damages, some of which are for substantial amounts. While these actions are being contested, their outcome is not predictable. Ashland’s results could be adversely affected by financial exposure to these liabilities. Insurance maintained by Ashland to protect against claims for damages alleged by third parties is subject to coverage limitations, depending on the nature of the risk insured. This insurance may not be sufficient to cover all of Ashland’s liabilities to others. In addition, insurance related to these types of risks may not be available now or, if available, may not be available in the future at commercially reasonable rates. Ashland’s ability to recover from its insurers for asbestos liabilities could also have an adverse impact on its results of operations. Projecting future asbestos costs is subject to numerous variables that are extremely difficult to predict. In addition to the significant uncertainties surrounding the number of claims that might be received, other variables include the type and severity of the disease alleged by each claimant, the long latency period associated with asbestos exposure, dismissal rates, costs of medical treatment, the impact of bankruptcies of other companies that are co-defendants in claims, uncertainties surrounding the litigation process from jurisdiction to jurisdiction and from case to case, and the impact of potential changes in legislative or judicial standards. Furthermore, any predictions with respect to these variables are subject to even greater uncertainty as the projection period lengthens. In light of these inherent uncertainties, Ashland believes that its asbestos reserves represent the best estimate within a range of possible outcomes. As a part of the process to develop these estimates of future asbestos costs, a range of long-term cost models was developed. These models are based on national studies that predict the number of people likely to develop asbestos-related diseases and are heavily influenced by assumptions regarding long-term inflation rates for indemnity payments and legal defense costs, as well as other variables mentioned previously. Because of the inherent uncertainties in projecting future asbestos liabilities and establishing appropriate reserves, Ashland’s actual asbestos costs could adversely affect its results of operations and, to the extent they exceed its reserves, could adversely affect its results of operations.

The impact of changing laws or regulations or the manner of interpretation or enforcement of existing rules could adversely impact Ashland’s financial performance and restrict its ability to operate its business or execute its strategies.

New laws or regulations, or changes in existing laws or regulations or the manner of their interpretation or enforcement, could increase Ashland’s cost of doing business and restrict its ability to operate its business or execute its strategies. This includes, among other things, the possible taxation under U.S. law of certain income from foreign operations, the possible taxation under foreign laws of certain income Ashland reports in other jurisdictions, the Pillar Two initiative of the Organization for Economic Co-operation and Development which introduces a 15% global minimum tax applied on a country-by-country basis to Ashland in many jurisdictions starting October 1, 2024, tariffs or quotas levied on Ashland products, raw materials or key components by certain countries, regulations related to the protection of private information of Ashland’s employees and customers, regulations issued by the U.S. Food and Drug Administration (and analogous non-U.S. agencies) affecting Ashland and its customers, compliance with the U.S. Foreign Corrupt Practices Act (and analogous non-U.S. laws) and the European Union’s Registration, Authorization and Restriction of Chemicals (REACH) regulation (and analogous non-EU initiatives), and potential operational impacts of General Data Protection Regulation (GDPR). Uncertainty associated with the passage of new laws, application of executive authority beyond the legislative process, as well as changes in and enforcement of existing laws, can limit Ashland’s ability to make and execute business plans effectively. In addition, compliance with laws and regulations is complicated by Ashland’s substantial and growing global footprint, which will require significant and additional resources to comprehend and ensure compliance with applicable laws in the more than one hundred countries where Ashland conducts business. Compliance with current and future regulations is further complicated by uncertainty around the reevaluation of international agreements by various countries, including the United States, and the resulting impact on regulatory regimes, customs regulations, tariffs, sanctions, and other transnational protocols.

Risks Related to Taxation

Imposition of new taxes, disagreements with tax authorities or additional tax liabilities could adversely affect Ashland’s business, financial condition, reputation or results of operations.

Ashland’s products are made, manufactured, distributed or sold in more than 100 countries and territories. A significant portion of Ashland’s revenues are generated outside the United States. As such, Ashland is subject to taxes in the United States as well as numerous foreign countries. Ashland’s future effective tax rates could be affected by changes in the mix of earnings in countries with differing tax rates, changes in the valuation of deferred tax assets and liabilities, changes in liabilities for uncertain

20


 

tax positions, cost of repatriations or changes in tax laws, regulations, administrative practices or their interpretation. Moreover, because Ashland is subject to the regular examination of its income tax returns by various tax authorities, the economic and political pressure to increase tax revenues in these jurisdictions may make resolving tax disputes even more difficult, and the final resolution of tax audits and any related litigation may differ from our historical provisions and accruals resulting in an adverse impact on our business, financial condition, reputation or results of operations. The Tax Cuts and Jobs Act (the Tax Act), enacted in December 2017, made significant changes to US tax law; many other countries or organizations, including those where Ashland has significant operations, are actively considering or enacting changes to tax laws which could significantly impact our tax rate and cash flows. The increasingly complex global tax environment, including changes in how United States multinational corporations are taxed, could adversely affect Ashland’s business, financial condition or results of operations.

Other than the one-time transition tax enacted by the Tax Act, Ashland will continue to be indefinitely reinvested in our foreign earnings. As such, Ashland has not accrued income taxes or foreign withholding taxes on undistributed earnings for most non-US subsidiaries because those earnings are intended to be indefinitely reinvested in the operations of those subsidiaries. If these earnings are needed for Ashland’s operations in the United States, the repatriation of such earnings could adversely affect its business, results of operations or financial condition.

The final distribution of Valvoline shares could result in significant tax liability to Ashland and its stockholders.

Ashland believes that the final distribution of Valvoline shares should be a nontaxable transaction for U.S. federal income tax purposes. Ashland has obtained a written opinion of counsel to the effect that the final distribution should qualify for non-recognition of gain and loss under Section 355 of the Internal Revenue Code of 1986, as amended (the “Code”). The opinion is based on certain assumptions and representations as to factual matters from Ashland and Valvoline, as well as certain covenants by those parties. The opinion cannot be relied upon if any of the assumptions, representations or covenants is incorrect, incomplete or inaccurate or is violated in any material respect, or if there are changes in law with retroactive effect. The opinion is not binding on the IRS or the courts, and it is possible that the IRS or a state or local taxing authority could take the position the final distribution resulted in the recognition of significant taxable gain by Ashland, in which case Ashland may be subject to material tax liabilities.

If the final distribution were determined not to qualify for non-recognition of gain and loss, then Ashland would recognize gain as if it had sold Valvoline common stock in a taxable transaction in an amount up to the fair market value of the Valvoline common stock it distributed in the final distribution. The tax liability resulting from such gain could have a material impact on Ashland’s operations.

ITEM 1B. UNRESOLVED STAFF COMMENTS

None.

ITEM 1C. CYBERSECURITY

Not applicable.

ITEM 2. PROPERTIES

Ashland’s corporate headquarters is located in Wilmington, Delaware. Principal offices of other major operations are located in Wilmington, Delaware (Life Sciences, Specialty Additives, Intermediates and Corporate); Bridgewater, New Jersey (Personal Care and Corporate); and Dublin, Ohio (Corporate) within the United States and Hyderabad, India; Warsaw, Poland; and Schaffhausen, Switzerland (each of which are shared service centers of Ashland’s and house Corporate and direct business segment personnel). All of these locations are leased, except for the Wilmington, Delaware site which is owned. Principal manufacturing, marketing and other materially important physical properties of Ashland and its subsidiaries are described within the applicable business units under “Item 1” in this Annual Report on Form 10-K. All of Ashland’s physical properties are owned or leased. Ashland believes its physical properties are suitable and adequate for the Company’s business. Additional information concerning leases may be found in Note J of Notes to Consolidated Financial Statements in this Annual Report on Form 10-K.

21


 

The following is a description of Ashland’s material legal proceedings. Ashland’s threshold for disclosing material environmental legal proceedings involving a governmental authority where potential monetary sanctions are involved is $1 million.

Asbestos-Related Litigation

Ashland is subject to liabilities from claims alleging personal injury caused by exposure to asbestos. Such claims result primarily from indemnification obligations undertaken in 1990 in connection with the sale of Riley Stoker Corporation (Riley), a former subsidiary. Although Riley was neither a producer nor a manufacturer of asbestos, its industrial boilers contained some asbestos containing components provided by other companies.

Hercules LLC (Hercules) (formerly Hercules Incorporated), an indirect wholly-owned subsidiary of Ashland, is also subject to liabilities from asbestos-related personal injury lawsuits involving claims which typically arise from alleged exposure to asbestos fibers from resin encapsulated pipe and tank products which were sold by one of Hercules’ former subsidiaries to a limited industrial market.

Ashland and Hercules are also defendants in lawsuits alleging exposure to asbestos at facilities formerly or presently owned or operated by Ashland or Hercules.

For additional detailed information regarding liabilities arising from asbestos-related litigation, see “Management’s Discussion and Analysis - Critical Accounting Policies - Asbestos Litigation” and Note M of Notes to Consolidated Financial Statements in this Annual Report on Form 10-K.

Environmental Proceedings

(a) CERCLA and Similar State Law Sites - Under the Comprehensive Environmental Response, Compensation and Liability Act of 1980 and similar state laws, Ashland and its subsidiaries may be subject to joint and several liability for cleanup costs in connection with alleged releases of hazardous substances at sites where it has been identified as a “potentially responsible party” (PRP). As of September 30, 2023, Ashland and its subsidiaries have been identified as a PRP by U.S. federal and state authorities, or by private parties seeking contribution, for the cost of environmental investigation and/or cleanup at 57 sites. These sites are currently subject to ongoing investigation and remedial activities, overseen by the United States Environmental Protection Agency (USEPA) or a state agency, in which Ashland or its subsidiaries are typically participating as a member of a PRP group. Generally, the types of relief sought include remediation of contaminated soil and/or groundwater, reimbursement for past costs of site cleanup and administrative oversight and/or long-term monitoring of environmental conditions at the sites. The ultimate costs are not predictable with assurance.

(b) Lower Passaic River, New Jersey Matters - Ashland, through two formerly owned facilities, and International Specialty Products (ISP), through a now-closed facility, have been identified as PRPs, along with approximately 70 other companies (the Cooperating Parties Group or the CPG), in a May 2007 Administrative Order of Consent (AOOC) with the USEPA. The parties are required to perform a remedial investigation and feasibility study (RI/FS) of the entire 17 miles of the Passaic River. In June 2007, the USEPA separately commenced a Focused Feasibility Study (FFS) as an interim measure. In accordance with the 2007 AOOC, in June 2012 the CPG voluntarily entered into another AOOC for an interim removal action focused solely at mile 10.9 of the Passaic River. The allocations for the 2007 AOOC and the 2012 removal action are based on interim allocations, are immaterial and have been accrued. In April 2014, the USEPA released the FFS. The CPG submitted the Draft RI/FS Report on April 30, 2015. The USEPA has released the FFS Record of Decision for the lower 8 miles and reached an agreement with another chemical company to conduct and pay for the remedial design. This chemical company has sued Ashland, ISP and numerous other defendants to recover past and future costs pursuant to the CERCLA. Ashland’s motion to dismiss was partially granted, and the surviving claims are in the early stages of discovery. Ashland and ISP participated in an USEPA allocation process that resulted in a partial settlement with the EPA. Possible future allocation proceedings are not expected to have a significant impact to Ashland.

For additional information regarding environmental matters and reserves, see Note M of Notes to Consolidated Financial Statements in this Annual Report on Form 10-K.

22


 

Other Pending Legal Proceedings

In addition to the matters described above, there are other various claims, lawsuits and administrative proceedings pending or threatened against Ashland and its current and former subsidiaries. Such actions are with respect to commercial matters, product liability, toxic tort liability, employment matters and other environmental matters which seek remedies or damages, some of which are for substantial amounts. While Ashland cannot predict with certainty the outcome of such actions, it believes that adequate reserves have been recorded as of September 30, 2023. There is a reasonable possibility that a loss exceeding amounts already recognized may be incurred related to these actions; however, Ashland believes that such potential losses would not be material as of September 30, 2023.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

23


 

PART II

ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

Market Information

Ashland’s Common Stock is listed on the NYSE (ticker symbol “ASH”) and has trading privileges on Nasdaq.

Holders

At October 31, 2023, there were approximately 8,565 holders of record of Ashland’s Common Stock.

Dividends

While we currently expect that quarterly cash dividends will continue to be paid in the future, such payments are at the discretion of our Board of Directors and will depend upon many factors, including our results of operations and liquidity position.

There were no sales of unregistered securities required to be reported under Item 5 of Form 10-K.

FIVE-YEAR TOTAL RETURN PERFORMANCE GRAPH

The following graph compares Ashland’s five-year cumulative total shareholder return with the cumulative total return of the S&P MidCap 400 index and one peer group of companies. Ashland is listed in the S&P MidCap 400 index. The cumulative total shareholder return assumes the reinvestment of dividends.

COMPARISON OF FIVE-YEAR CUMULATIVE TOTAL RETURN

ASHLAND, S&P MIDCAP 400 INDEX AND PEER GROUP

https://cdn.kscope.io/83d9d1eccb376045c3d3f02f9b457cde-img138869020_2.jpg 

 

 

 

2018

 

2019

 

2020

 

2021

 

2022

 

2023

Ashland

 

100

 

93

 

87

 

111

 

120

 

105

S&P MidCap 400

 

100

 

98

 

96

 

138

 

117

 

135

Peer Group - Materials

 

100

 

101

 

111

 

142

 

126

 

150

The peer group consists of the following industry indices:

Peer Group – Materials: S&P 500 Materials (large-cap) and S&P MidCap 400 Materials. As of September 30, 2023, this peer group consisted of 57 companies.

24


 

Repurchases of Company Common Stock

Share repurchase activity during the three months ended September 30, 2023 was as follows:

 

Q4 Fiscal Periods

 

Total Number
of Shares
Purchased

 

 

Average
Price Paid
per Share,
including
commission

 

 

Total Number of
Shares
Purchased as
Part of Publicly
Announced
Plans or
Programs

 

 

Dollar Value
of Shares
That May Yet
Be Purchased
Under the
Plans or
Programs
(in millions)
(a)

 

July 1, 2023 to July 31, 2023

 

 

 

 

$

 

 

 

 

 

$

1,000

 

August 1, 2023 to August 31, 2023

 

 

 

 

 

 

 

 

 

 

 

1,000

 

September 1, 2023 to September 30, 2023

 

 

 

 

 

 

 

 

 

 

 

1,000

 

Total

 

 

 

 

 

 

 

 

 

 

 

1,000

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(a)
On June 28, 2023, Ashland's board of directors authorized a new evergreen $1 billion common share repurchase program (2023 stock repurchase program). The new authorization terminates and replaces the company's 2022 stock repurchase program, which had $200 million outstanding at the date of termination.

ITEM 6. [RESERVED]

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

See Management’s Discussion and Analysis of Financial Condition and Results of Operations on pages M-1 through M-42.

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

See Quantitative and Qualitative Disclosures about Market Risk on page M-42.

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

The consolidated financial statements of Ashland presented in this Annual Report on Form 10-K are listed in the index on page F-1.

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

None.

ITEM 9A. CONTROLS AND PROCEDURES

Disclosure Controls and Procedures – As of September 30, 2023, Ashland, under the supervision and with the participation of Ashland’s management, including Ashland’s Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of Ashland’s disclosure controls and procedures as defined in Exchange Act Rules 13a-15(e) and 15d-15(e). Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that the disclosure controls and procedures were effective as of September 30, 2023.

Internal Control over Financial Reporting - See Management’s Report on Internal Control Over Financial Reporting on page F-2 and the Reports of the Independent Registered Public Accounting Firm on pages F-3 and F-4.

Changes in Internal Control over Financial Reporting – There have been no changes in Ashland’s internal control over financial reporting that occurred during the quarter ended September 30, 2023, that have materially affected, or are reasonably likely to materially affect, Ashland’s internal control over financial reporting.

ITEM 9B. OTHER INFORMATION

Insider Trading Arrangements

None.

25


 

ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS

None.

26


 

PART III

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

The information required by this Item is incorporated herein by reference to the sections captioned “Proposal One - Election of Directors,” “Executive Officers,” “Delinquent Section 16(a) Reports,” “Corporate Governance - Governance Principles,” “Corporate Governance - Stockholder Nominations of Directors,” “Corporate Governance – Insider Trading Policy,” and “Corporate Governance - Committees and Meetings of the Board of Directors” in the Proxy Statement for Ashland’s 2024 Annual Meeting of Stockholders. Ashland plans to file such Proxy Statement within 120 days after September 30, 2023, the end of Ashland’s fiscal year.

ITEM 11. EXECUTIVE COMPENSATION

The information required by this Item is incorporated herein by reference to the sections captioned “Director Compensation,” “Compensation Committee Interlocks and Insider Participation,” “Executive Compensation,” and “Compensation Committee Report,” in the Proxy Statement for Ashland’s 2024 Annual Meeting of Stockholders. The Compensation Committee Report to be included in such Proxy Statement shall be deemed to be furnished in this report and shall not be incorporated by reference into any filing under the Securities Act of 1933 or the Exchange Act as a result of such furnishing in this Item 11. Ashland plans to file such Proxy Statement within 120 days after September 30, 2023, the end of Ashland’s fiscal year.

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

The information required by this Item is incorporated herein by reference to the sections captioned “Ashland Common Stock Ownership of Certain Beneficial Owners,” and “Ashland Common Stock Ownership of Directors and Executive Officers of Ashland” in the Proxy Statement for Ashland’s 2024 Annual Meeting of Shareholders. Ashland plans to file such Proxy Statement within 120 days after September 30, 2023, the end of Ashland’s fiscal year.

 

 

27


 

The following table summarizes the equity compensation plans under which Ashland Common Stock may be issued as of September 30, 2023.

 

Equity Compensation Plan Information

Plan Category

Number of

securities

to be issued upon

exercise of

outstanding

options,

warrants

and rights

 

Weighted-average

exercise price of

outstanding

options, warrants

and rights

 

Number of

securities

remaining

available

for future

issuance

under equity

compensation

plans

(excluding

securities

reflected

in column (a))

(a)

 

(b)

 

(c)

Equity compensation plans

   approved by security holders

596,158

(1)

 

 $

65.22

 

(2)

10,124,365

(3)

Equity compensation plans not

   approved by security holders

50,407

(4)

 

 

1,276,934

(5)

Total

646,565

 

$

65.22

 

(2)

11,401,299

 

(1)
This figure includes 31,694 net shares that could be issued under stock-settled SARs under the Amended and Restated 2011 Ashland Inc. Incentive Plan (“2011 Incentive Plan”), 165,813 net shares that could be issued under stock-settled SARs, 9,263 net shares that could be issued under stock-settled SARs, 46,161 shares that could be issued under stock settled restricted stock units under the Ashland Global Holdings Inc. 2018 Omnibus Incentive Compensation Plan (the “2018 Omnibus Plan”), 162,660 shares that could be issued under stock settled restricted stock units under the Ashland Global Holdings Inc. 2021 Omnibus Incentive Compensation Plan (the “2021 Omnibus Plan”), based upon the closing price of Ashland Common Stock on the NYSE as of September 30, 2023 of $81.68. Additionally, this figure includes 37,924 performance units for the fiscal 2021-2023 performance period payable in Ashland Common Stock under the 2018 Omnibus Plan, 89,663 performance units for the fiscal 2022-2024 performance period payable in Ashland Common Stock under the 2021 Omnibus Plan and 38,166 performance units for the fiscal 2023-2025 performance period payable in Ashland Common Stock under the 2021 Omnibus Plan, estimated assuming target performance is achieved. Also included in the figure are 14,814 shares to be issued under the pre-2005 Deferred Compensation Plan for Employees payable in Ashland Common Stock upon termination of employment or service with Ashland.
(2)
The weighted-average exercise price excludes shares in Ashland Common Stock which may be distributed under the deferred compensation plans and the deferred restricted stock, and performance share units and restricted stock units which may be distributed under the 2011 Incentive Plan, the 2015 Incentive Plan and the 2018 Omnibus Plan, as described in footnotes (1) and (4) in this table.
(3)
This figure includes 6,332,994 available for issuance under the Ashland Global Holdings Inc. 2021 Omnibus Plan, 105,610 shares available for issuance under the pre-2005 Deferred Compensation Plan for Employees (closed) and 352,931 shares available for issuance under the pre-2005 Deferred Compensation Plan for Non-Employee Directors (closed). Under the 2018 Incentive Plan, full-value awards, which include all awards other than stock options and SARs, reduce the share reserve on a 2-to-1 basis. The remaining balance of shares available for grant under the 2018 Omnibus Plan are now available for grant under the 2021 Omnibus Plan and are included in the numbers of shares available for issuance under the 2021 Omnibus Plan. This figure also includes 81,233 shares available for issuance under the 2006 Incentive Plan, 2,572,476 shares available for issuance under the 2011 Incentive Plan and 679,121 shares available for issuance under the 2015 Incentive Plan; however, these plans are closed for new issuances and the only shares remaining to be issued are shares paid in lieu of dividends and for the 2015 Incentive Plan, shares to be issued for unvested performance units and restricted stock units.
(4)
This figure includes 36,060 shares to be issued under the Deferred Compensation Plan for Employees (2005), which is described in the “Non-Qualified Deferred Compensation-Ashland Employees’ Deferral Plan” section of Ashland’s proxy statement, and 14,347 shares to be issued under the Deferred Compensation Plan for Non-Employee Directors (2005), which is described in the “Compensation of Directors” section of Ashland’s proxy statement, payable in Ashland Common Stock upon termination of employment or service with Ashland. Because these plans are not equity compensation plans as defined by the rules of the NYSE, neither plan required approval by Ashland’s stockholders.
(5)
This figure includes 615,031 shares available for issuance under the Deferred Compensation Plan for Employees (2005) and 661,903 shares available for issuance under the Deferred Compensation Plan for Non-Employee Directors (2005). Because these plans are not equity compensation plans as defined by the rules of the NYSE, neither plan required approval by Ashland’s stockholders.

 

The information required by this Item is incorporated herein by reference to the sections captioned “Corporate Governance - Director Independence and Certain Relationships,” “Corporate Governance - Related Person Transaction Policy,” and “Audit Committee Report” in in the Proxy Statement for Ashland’s 2024 Annual Meeting of Stockholders. Ashland plans to file such Proxy Statement within 120 days after September 30, 2023, the end of Ashland’s fiscal year.

28


 

ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES

The information required by this Item is incorporated herein by reference to the sections captioned “Audit Committee Report” and “Proposal Two - Ratification of Independent Registered Public Accountants” in the Proxy Statement for Ashland’s 2024 Annual Meeting of Stockholders. Ashland plans to file such Proxy Statement within 120 days after September 30, 2023, the end of Ashland’s fiscal year.

29


 

PART IV

ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

(a) Documents filed as part of this Report

(1) Financial Statements; and

(2) See Item 15(b) in this Annual Report on Form 10-K

The consolidated financial statements of Ashland presented in this Annual Report on Form 10-K are listed in the index on page F-1.

Schedules other than that listed above have been omitted because of the absence of the conditions under which they are required or because the information required is shown in the consolidated financial statements or the notes thereto. Separate financial statements of unconsolidated affiliates are omitted because each company does not constitute a significant subsidiary using the 20% tests when considered individually.

(b) Documents required by Item 601 of Regulation S-K

2.1

Stock and Asset Purchase Agreement, dated as of February 18, 2014, between Ashland Inc. and CD&R Seahawk Bidco, LLC (filed as Exhibit 2.1 to Ashland’s Form 8-K filed on February 24, 2014 (SEC File No. 001-32532), and incorporated herein by reference).

 

 

 

2.2

Sale and Purchase Agreement related to the ASK Chemicals Group, dated April 8, 2014, among Ashland Inc., Ashland International Holdings, Inc., Clariant Produkte (Deutschland) GmbH, Clariant Corp., mertus 158. GmbH, Ascot US Bidco Inc. and Ascot UK Bidco Limited (filed as Exhibit 2.1 to Ashland’s Form 8-K filed on April 14, 2014 (SEC File No. 001-32532), and incorporated herein by reference).

 

 

 

2.3

Agreement and Plan of Merger dated May 31, 2016, by and among Ashland Inc., Ashland Global Holdings Inc. and Ashland Merger Sub Corp. (filed as Exhibit 2.1 to Ashland’s Form 8-K filed on May 31, 2016 (SEC File No. 001-32532), and incorporated herein by reference).

 

 

 

2.4

Stock and Asset Purchase Agreement, dated November 14, 2018, between Ashland Global Holdings Inc. and INEOS Enterprises Holdings Limited (pursuant to Item 601(b)(2) of Regulation S-K, exhibits, schedules and certain annexes to the Stock and Asset Purchase Agreement have been omitted; exhibits, schedules and annexes will be supplementally provided to the SEC upon request) (filed as Exhibit 2.1 to Ashland’s Form 8-K filed on November 20, 2018 (SEC File No. 333-211719), and incorporated herein by reference.)

 

 

 

2.5

First Amendment to Stock and Asset Purchase Agreement, dated July 1, 2019, between Ashland Global Holdings Inc. and INEOS Enterprises Holdings Limited (pursuant to Item 601(b)(2) of Regulation S-K, exhibits, schedules and certain annexes to the Stock and Asset Purchase Agreement have been omitted; exhibits, schedules and annexes will be supplementally provided to the SEC upon request) (filed as Exhibit 2.1 to Ashland’s Form 8-K filed on July 8, 2019 (SEC File No. 333-211719) and incorporated herein by reference).

 

 

 

2.6

Second Amendment to Stock and Asset Purchase Agreement, dated July 30, 2019, between Ashland Global Holdings Inc. and INEOS Enterprises Holdings Limited (pursuant to Item 601(b)(2) of Regulation S-K, exhibits, schedules and certain annexes to the Stock and Asset Purchase Agreement have been omitted; exhibits, schedules and annexes will be supplementally provided to the SEC upon request (filed as Exhibit 2.1 to Ashland’s Form 8-K filed on August 2, 2019 (SEC File No. 333-211719) and incorporated herein by reference).

 

 

 

 

2.7

Asset Purchase Agreement dated July 25, 2020, by and between Ashland LLC and AOC Materials LLC (filed as Exhibit 2.1 to Ashland’s Form 8-K filed on July 27, 2020 (SEC File No. 333-211719 and incorporated herein by reference).

 

 

 

 

2.8

Master Asset Purchase Agreement, dated January 18, 2021, entered into by and between Schülke & Mayr GmbH, ISP Marl Holdings and Ashland Industries Europe GmbH (filed as Exhibit 2.1 to Ashland’s Form 8-K filed on January 22, 2021 (SEC File No.333-211719) and incorporated herein by reference).

 

 

 

30


 

2.9

Amendment Agreement to the Master Purchase Agreement regarding the acquisition of the Personal Care Business of Schülke & Mayr GmbH dated April 29, 2021, filed as Exhibit 2.2 to Ashland’s Form 10-Q filed on July 29, 2021 (SEC File No.333-211719) and incorporated herein by reference).

 

 

 

2.10

Purchase and Sale Agreement, dated as of August 30, 2021, between Ashland LLC and Arkema, filed as Exhibit 2.1 to Ashland’s Form 8-K filed on August 31, 2021 (SEC File No.333-211719) and incorporated herein by reference).

 

 

 

2.11

Amendment No. 1 to the Purchase and Sale Agreement, dated as of February 28, 2022, by and between Arkema and Ashland LLC (filed as Exhibit 2.1 to Ashland’s Form 8-K filed on February 28, 2022 (SEC File No.333-211719) and incorporated herein by reference).

 

 

 

2.12

Stock Purchase Agreement, dated April 14, 2017, by and among Ashland LLC, Pharmachem Laboratories, Inc., the holders of common stock of Pharmachem Laboratories, Inc., Dr. David Peele, and Photon SH Representative LLC, solely as the shareholders’ representative (filed as Exhibit 2.1 to Ashland’s Form 8-K filed on May 18, 2017 (SEC File No. 333-211719) and incorporated herein by reference).

 

 

 

2.13

Amendment No. 1 to the Stock Purchase Agreement, dated May 16, 2017, by and among Ashland LLC, Pharmachem Laboratories, Inc., the holders of common stock of Pharmachem Laboratories, Inc., Dr. David Peele, and Photon SH Representative LLC, solely as the shareholders’ representative (filed as Exhibit 2.2 to Ashland’s Form 8-K filed on May 18, 2017 (SEC File No. 333-211719) and incorporated herein by reference).

 

 

 

2.14

Amendment No. 2 to the Stock Purchase Agreement, dated August 23, 2017, by and among Ashland LLC, Pharmachem Laboratories, Inc., the holders of common stock of Pharmachem Laboratories, Inc., Dr. David Peele, and Photon SH Representative LLC, solely as the shareholders’ representative (filed as Exhibit 10.84 to Ashland’s Form 10-K for the fiscal year ended September 30, 2017 (SEC File No. 333-211719), and incorporated by reference herein).

 

 

 

3.1

Amended and Restated Articles of Incorporation of Ashland Global Holdings Inc. (filed as Exhibit 3.1 to Ashland’s Form 8-K filed on September 20, 2016 (SEC File No. 001-32532)) and incorporated by reference herein).

 

 

 

3.2

Certificate of Ownership & Merger, amending the Company’s Amended and Restated Certificate of Incorporation (filed as Exhibit 3.1 to Ashland’s Form 8-K filed on August 1, 2022 (SEC File No. 001-32532) and incorporated by reference herein).

 

 

 

3.3

By-laws of Ashland Inc. (Amended and Restated as of September 20, 2022) (filed as Exhibit 3.1 to Ashland’s Form 8-K filed on September 20, 2022 (SEC File No. 333-211719) and incorporated by reference herein).

 

 

 

4.1

Pursuant to Item 601(b)(4)(iii)(A) of Regulation S-K, copies of instruments defining the rights of holders of long-term debt of Ashland and all of its subsidiaries are not filed, Ashland agrees to furnish a copy of such instruments with the SEC upon request.

 

 

 

4.2

Warrant Agreement dated July 27, 1999 between Hercules and The Chase Manhattan Bank, as warrant agent (filed as Exhibit 4.4 to Hercules’ Form 8-K filed on July 28, 1999 (SEC File No. 001-00496), and incorporated herein by reference).

 

 

 

4.3

Form of Series A Junior Subordinated Deferrable Interest Debentures (filed as Exhibit 4.5 to Hercules’ Form 8-K filed on July 28, 1999 (SEC File No. 001-00496), and incorporated herein by reference).

 

 

 

4.4

Form of CRESTSM Unit (filed as Exhibit 4.7 to Hercules’ Form 8-K filed on July 28, 1999 (SEC File No. 001-00496), and incorporated herein by reference).

 

 

 

4.5

Form of Warrant (filed as Exhibit 4.8 to Hercules’ Form 8-K filed on July 28, 1999 (SEC File No. 001-00496), and incorporated herein by reference).

 

 

 

4.6

Form of $100,000,000 6.6% Debenture due August 27, 2027 (filed as Exhibit 4.2 to Hercules’ Form 8-K filed on July 30, 1997 (SEC File No. 001-00496), and incorporated herein by reference).

 

 

 

31


 

4.7

Indenture, dated as of August 7, 2012, between Ashland Inc. and U.S. Bank N.A., as Trustee (filed as Exhibit 4.1 to Ashland’s Form 8-K filed on September 21, 2012 (SEC File No. 001-32532), and incorporated herein by reference).

 

 

 

4.8

First Supplemental Indenture, dated as of February 26, 2013, between Ashland Inc. and U.S. Bank National Association, as Trustee, in respect of the senior notes due 2022 (filed as Exhibit 4.11 to Ashland’s Form 10-K for the fiscal year ended September 30, 2013 (SEC File No. 001-32532), and incorporated herein by reference).

 

 

 

4.9

Indenture, dated as of February 26, 2013, between Ashland Inc. and U.S. Bank National Association, as Trustee (filed as Exhibit 4.3 to Ashland’s Form 8-K filed on February 27, 2013 (SEC File No. 001- 32532), and incorporated herein by reference).

 

 

 

4.10

First Supplemental Indenture, dated as of February 26, 2013, between Ashland Inc. and U.S. Bank National Association, as Trustee, in respect of the senior notes due 2016, 2018 and 2043 (filed as Exhibit 4.4 to Ashland’s Form 8-K filed on February 27, 2013 (SEC File No. 001-32532), and incorporated herein by reference).

 

 

 

4.11

Second Supplemental Indenture, dated as of March 14, 2013, between Ashland Inc. and U.S. Bank National Association, as Trustee, in respect of the senior notes due 2043 (filed as Exhibit 4.2 to Ashland’s Form 8-K filed on March 18, 2013 (SEC File No. 001-32532), and incorporated herein by reference).

 

 

 

4.12

First Supplemental Indenture as of August 1, 2022, to the Trust Indenture in respect of the 2031 Notes dated as of August 18, 2021, by and among Ashland Global Holdings Inc. (now Ashland Inc.), U.S. Bank Trust Company, National Association, as trustee (filed as Exhibit 4.12 to Ashland's Form 10-K for the fiscal year ended September 30, 2022, filed on November 21, 2022 (SEC File No. 333-211719), and incorporated herein by reference).

 

 

 

4.13

Third Supplemental Indenture dated October 19, 2016, among Ashland LLC, Ashland Global Holdings Inc. and US Bank National Association, to the Indenture dated as of February 26, 2013 between Ashland LLC and US Bank National Association (filed as Exhibit 4.2 to Ashland’s Form 8-K filed on October 20, 2016 (SEC File No. 333-211719), and incorporated herein by reference).

 

 

 

4.14

Fourth Supplemental Indenture dated August 1, 2022, to the Trust Indenture dated as of February 26, 2013, between Ashland Global Holdings Inc. (now Ashland Inc.) and U.S. Bank Trust Company, National Association, as trustee (filed as Exhibit 4.14 to Ashland's Form 10-K for the fiscal year ended September 30, 2022, filed on November 21, 2022 (SEC File No. 333-211719), and incorporated herein by reference).

 

 

 

4.15

Indenture dated January 23, 2020, among Ashland Services B.V., Ashland Global Holdings Inc., Ashland LLC and U.S. Bank National Association, as trustee, in respect of the Senior Euro-Denominated Notes due 2028 (filed as Exhibit 4.1 to Ashland’s Form 8-K filed on January 23, 2020 (SEC File No. 333-211719) and incorporated herein by reference).

 

4.15(a)

Description of Capital Stock (filed as Exhibit 4.14(a) to Ashland’s Form 10-K for the fiscal year ended September 30, 2019 (SEC File No. 333-211719) and incorporated herein by reference).

 

 

 

4.15(b)

Description of 6.875% Senior Notes due 2043 (filed as Exhibit 4.14(b) to Ashland’s Form 10-K for the fiscal year ended September 30, 2019 (SEC File No. 333-211719) and incorporated herein by reference).

 

 

 

4.15(c)

Description of 4.750% Senior Notes due 2022 (filed as Exhibit 4.14(c) to Ashland’s Form 10-K for the fiscal year ended September 30, 2019 (SEC File No. 333-211719) and incorporated herein by reference).

 

 

 

4.16

Indenture dated August 18, 2021, among Ashland LLC, Ashland Global Holdings Inc. and U.S. Bank National Association, as trustee, in respect of the Notes due 2031 (filed as Exhibit 4.1 to Ashland’s Form 8-K filed on August 18, 2021 (SEC File No. 333-211719), and incorporated herein by reference).

 

 

The following Exhibits 10.1 through 10.80 are contracts or compensatory plans or arrangements or management contracts required to be filed as exhibits pursuant to Items 601(b)(10)(ii)(A) and 601(b)(10)(iii)(A) and (B) of Regulation S-K.

 

10.1

Amended and Restated Ashland Inc. Deferred Compensation Plan for Non-Employee Directors (2005) (filed as Exhibit 10.4 to Ashland’s Form 10-K for the fiscal year ended September 30, 2008 (SEC File No. 001-32532), and incorporated herein by reference).

32


 

 

 

 

10.2

Amendment to the Amended and Restated Ashland Inc. Deferred Compensation Plan for Non-Employee Directors (2005) (filed as Exhibit 10.4 to Ashland’s Form 10-Q for the quarter ended March 31, 2015 (SEC File No. 001-32532), and incorporated herein by reference).

 

 

 

10.3

Amended and Restated Ashland Global Holdings Inc. Deferred Compensation Plan for Non-Employee Directors (2005) effective as of January 1, 2017 (filed as Exhibit 10.4 to Ashland’s Form 10-Q for the quarter ended December 31, 2016 (SEC File No. 333-211719), and incorporated herein by reference).

 

 

 

10.4

Amended and Restated Ashland Inc. Deferred Compensation Plan for Employees (2005) (filed as Exhibit 10.3 to Ashland’s Form 10-K for the fiscal year ended September 30, 2008 (SEC File No. 001-32532) and incorporated herein by reference).

 

 

 

10.5

 

Ashland Global Holdings Inc. Deferred Compensation Plan for Employees (Amended and Restated Effective as of May 22, 2019) (filed as Exhibit 10.1 to Ashland’s Form10-Q for the quarter ended June 30, 2019 (SEC File No. 333-211719), and incorporated herein by reference).

 

 

 

10.6

 

Ashland Global Holdings Inc. Deferred Compensation Plan for Non-Employee Directors (Amended and Restated as of May 22, 2019) (filed as Exhibit 10.2 to Ashland’s Form 10-Q for the quarter ended June 30, 2019 (SEC File No. 333-21179), and incorporated herein by reference).

 

 

 

10.7

Ashland Supplemental Defined Contribution Plan for Certain Employees (filed as Exhibit 10.3 to Ashland’s Form 10-Q for the quarter ended March 31, 2011 (SEC File No. 001-32532), and incorporated herein by reference) (Frozen).

 

 

 

10.8

Amended and Restated 2011 Ashland Inc. Incentive Plan (filed as Exhibit 10.2 to Ashland’s Form 8-K filed on February 1, 2013 (SEC File No. 001-32532), and incorporated herein by reference).

 

 

 

10.9

Amended and Restated 2015 Ashland Global Holdings Inc. Incentive Plan (filed as Exhibit 10.21 to Ashland’s Form 10-K for the fiscal year ended September 30, 2016 (SEC File No. 333-211719), and incorporated by reference herein).

 

 

 

10.10

Form of Stock Appreciation Rights Award Agreement under the Amended and Restated 2011 Ashland Inc. Incentive Plan (filed as Exhibit 10.16 to Ashland’s Form 10-K for the fiscal year ended September 30, 2014 (SEC File No. 001-32532), and incorporated herein by reference).

 

 

 

10.11

Form of Restricted Stock Award Agreement under the Amended and Restated 2011 Ashland Inc. Incentive Plan (filed as Exhibit 10.18 to Ashland’s Form 10-K for the fiscal year ended September 30, 2014 (SEC File No. 001-32532), and incorporated herein by reference).

 

 

 

10.12

Form of Restricted Stock Award Agreement under the Amended and Restated 2015 Ashland Global Holdings Inc. Incentive Plan (filed as Exhibit 10.5 to Ashland’s Form 10-Q for the quarter ended March 31, 2015 (SEC File No. 001-32532), and incorporated herein by reference).

 

 

 

10.13

Form of Stock Appreciation Rights Award Agreement under the Amended and Restated 2015 Ashland Global Holdings Inc. Incentive Plan (filed as Exhibit 10.7 to Ashland’s Form 10-Q for the quarter ended March 31, 2015 (SEC File No. 001-32532), and incorporated herein by reference).

 

 

 

10.14

Form of Restricted Stock Award Agreement under the Amended and Restated 2015 Ashland Global Holdings Inc. Incentive Plan (Double-Trigger Form) (filed as Exhibit 10.2 to Ashland’s Form 8-K filed on July 20, 2015 (SEC File No. 001-32532), and incorporated herein by reference).

 

 

 

10.15

Form of Performance-Based Restricted Stock Award Agreement (filed as Exhibit 10.3 to Ashland’s Form 8-K filed on October 9, 2015 (SEC File No. 001-32532), and incorporated herein by reference).

 

 

 

10.16

Form of Restricted Stock Award Agreement under the Amended and Restated 2015 Ashland Global Holdings Inc. Incentive Plan (Double-Trigger Form) (filed as Exhibit 10.37 to Ashland’s Form 10-K for the fiscal year ended September 30, 2016 (SEC File No. 333-211719), and incorporated by reference herein).

 

 

 

10.17

Form of Restricted Stock Unit Award Agreement under the Amended and Restated 2015 Ashland Global Holdings Inc. Incentive Plan (Double-Trigger Form) (filed as Exhibit 10.38 to Ashland’s Form 10-K for the fiscal year ended September 30, 2016 (SEC File No. 333-211719), and incorporated by reference herein).

 

 

 

33


 

10.18

Form of Stock Appreciation Rights Award Agreement under the Amended and Restated 2015 Ashland Global Holdings Inc. Incentive Plan (Double-Trigger Form) (filed as Exhibit 10.39 to Ashland’s Form 10-K for the fiscal year ended September 30, 2016 (SEC File No. 333-211719), and incorporated by reference herein).

 

 

 

10.19

Form of Performance Unit (LTIP) Award Agreement under the Amended and Restated 2015 Ashland Global Holdings Inc. Incentive Plan (Double-Trigger Form) (filed as Exhibit 10.40 to Ashland’s Form 10-K for the fiscal year ended September 30, 2016 (SEC File No. 333-211719), and incorporated by reference herein).

 

 

 

10.20

Form of Indemnification Agreement between Ashland and members of its Board of Directors (filed as Exhibit 10.2 to Ashland’s Form 8-K filed on September 20, 2016 (SEC File No. 333-211719), and incorporated herein by reference).

 

 

 

10.21

 

Form of Cash-Settled Performance Unit (LTIP) Award Agreement under the Amended and Restated 2015 Ashland Global Holdings Inc. Incentive Plan (Double-Trigger Form) (filed as Exhibit 10.59 to Ashland’s Form 10-K for the fiscal year ended September 30, 2016 (SEC File No. 333-211719), and incorporated by reference herein).

 

 

 

10.22

Amended and Restated Hercules Deferred Compensation Plan effective January 1, 2008 (filed as Exhibit 10.8 to Ashland’s Form 10-K for the fiscal year ended on September 30, 2010 (SEC File No. 001-32532), and incorporated herein by reference).

 

 

 

10.23

Amendment to the Amended and Restated Hercules Deferred Compensation Plan dated September 30, 2016 (annuity cash-out) (filed as Exhibit 10.61 to Ashland’s Form 10-K for the fiscal year ended September 30, 2016 (SEC File No. 333-211719), and incorporated by reference herein).

 

 

 

10.24

Ashland Global Holdings Inc. 2018 Omnibus Incentive Compensation Plan (filed as Exhibit 10.1 to Ashland’s Form 8-K filed on January 26, 2018 (SEC File No. 333-211719), and incorporated herein by reference).

 

 

 

10.25

Form of Stock-Settled Restricted Stock Unit Award Agreement under the Ashland Global Holdings Inc. 2018 Omnibus Incentive Compensation Plan (filed as Exhibit 10.2 to Ashland’s Form 8-K filed on January 26, 2018 (SEC File No. 333-211719), and incorporated herein by reference).

 

 

 

10.26

Form of Restricted Stock Award Agreement under the Ashland Global Holdings Inc. 2018 Omnibus Incentive Compensation Plan (filed as Exhibit 10.3 to Ashland’s Form 8-K filed on January 26, 2018 (SEC File No. 333-211719), and incorporated herein by reference).

 

 

 

10.27

Form of Stock Appreciation Rights Award Agreement under the Ashland Global Holdings Inc. 2018 Omnibus Incentive Compensation Plan (filed as Exhibit 10.4 to Ashland’s Form 8-K filed on January 26, 2018 (SEC File No. 333-211719), and incorporated herein by reference).

 

 

 

10.28

Form of Performance Unit Award Agreement under the Ashland Global Holdings Inc. 2018 Omnibus Incentive Compensation Plan (filed as Exhibit 10.5 to Ashland’s Form 8-K filed on January 26, 2018 (SEC File No. 333-211719), and incorporated herein by reference).

 

 

 

10.29

Form of Cash-Settled Restricted Stock Unit Award Agreement under the Ashland Global Holdings Inc. 2018 Omnibus Incentive Compensation Plan (filed as Exhibit 10.6 to Ashland’s Form 8-K filed on January 26, 2018 (SEC File No. 333-211719), and incorporated herein by reference).

 

 

 

10.30

Ashland Global Holdings Inc. NonQualified Defined Contribution Plan (Amended and Restated as of May 22, 2019) (filed as Exhibit 10.3 to Ashland’s Form 10-Q for the quarter ended June 30, 2019 (SEC File No. 333-211719), and incorporated herein by reference).

 

 

 

10.31

Ashland Global Holdings Inc. Supplemental Defined Contribution Plan for Certain Employees (Amended and Restated as of May 22, 2019) (filed as Exhibit 10.39 to Ashland’s Form 10-K filed on November 25, 2019 (SEC File No. 333-211719) and incorporated herein by reference).

 

 

 

10.32

Form of Restricted Stock Award Agreement under the Ashland Global Holdings Inc. 2018 Omnibus Incentive Compensation Plan (with pro-rata vesting upon death, disability and retirement) (filed as Exhibit 10.5 to Ashland’s Form 10-Q for the quarter ended June 30, 2019 (SEC File No. 333-211719), and incorporated herein by reference).

34


 

 

 

 

10.33

Form of Stock Appreciation Rights Award Agreement (Stock Settled) under the Ashland Global Holdings Inc. 2018 Omnibus Incentive Compensation Plan (with pro-rata vesting upon death, disability and retirement) (filed as Exhibit 10.6 to Ashland’s Form 10-Q for the quarter ended June 30, 2019 (SEC File No. 333-211719), and incorporated herein by reference).

 

 

 

10.34

Form of Restricted Stock Unit Award Agreement under the Ashland Global Holdings Inc. 2018 Omnibus Incentive Compensation Plan (with pro-rata vesting upon death, disability and retirement) (filed as Exhibit 10.7 to Ashland’s Form 10-Q for the quarter ended June 30, 2019 (SEC File No. 333-211719), and incorporated herein by reference).

 

 

 

10.35

Form of Stock-Settled Performance Unit Award Agreement under the Ashland Global Holdings Inc. 2018 Omnibus Incentive Compensation Plan (with pro-rata vesting upon death, disability and retirement) (filed as Exhibit 10.8 to Ashland’s Form 10-Q for the quarter ended June 30, 2019 (SEC File No. 333-211719), and incorporated herein by reference).

 

 

 

10.36

Offer Letter dated as of October 8, 2019, entered into by Guillermo Novo and Ashland Global Holdings Inc. (filed as Exhibit 10.1 to Ashland’s Form 8-K filed on October 8, 2019 (SEC File No. 333-211719) and incorporated herein by reference).

 

 

 

10.37

Form of Chief Executive Officer Change in Control Agreement (filed as Exhibit 10.4 to Ashland’s Form 10-Q filed on January 29, 2020 (SEC File No. 333-211719) and incorporated herein by reference).

 

 

 

10.38

Amendment to Ashland’s Severance Pay Plan dated January 29, 2020 (filed as Exhibit 10.1 to Ashland’s Form 10-Q filed on May 6, 2020 (SEC File No: 333-211719) and incorporated herein by reference).

 

 

 

10.39

Ashland Global Holdings Inc. 2021 Omnibus Incentive Compensation Plan (filed as Exhibit 10.1 to Ashland’s Form 8-K filed on February 3, 2021 (SEC File No. 333-211719) and incorporated herein by reference).

 

 

 

10.40

Form of Stock-Settled Restricted Stock Unit Award Agreement (filed as Exhibit 10.2 to Ashland’s Form 8-K filed on February 3, 2021 (SEC File No. 333-211719) and incorporated herein by reference).

 

 

 

10.41

Form of Restricted Share Award Agreement (filed as Exhibit 10.3 to Ashland’s Form 8-K filed on February 3, 2021 (SEC File No. 333-211719) and incorporated herein by reference).

 

 

 

10.42

Form of Stock Appreciation Rights Award Agreement (filed as Exhibit 10.4 to Ashland’s Form 8-K filed on February 3, 2021 (SEC File No. 333-211719) and incorporated herein by reference).

 

 

 

10.43

Form of Performance Unit Award Agreement (filed as Exhibit 10.5 to Ashland’s Form 8-K filed on February 3, 2021 (SEC File No. 333-211719) and incorporated herein by reference).

 

 

 

10.44

Form of Cash-Settled Restricted Stock Unit Award Agreement (filed as Exhibit 10.6 to Ashland’s Form 8-K filed on February 3, 2021 (SEC File No. 333-211719) and incorporated herein by reference).

 

 

 

10.45

Form of Cash Settled Restricted Stock Equivalent Award Agreement for Non-U.S. Participants under the Ashland Global Holdings Inc. 2021 Omnibus Incentive Compensation Plan (filed as Exhibit 10.2 to Ashland’s Form 8-K filed on August 6, 2021 (SEC File No. 333-211719) and incorporated herein by reference).

 

 

 

10.46

Form of Cash Settled Performance Unit Award Agreement for Non-U.S. Participants under the Ashland Global Holdings Inc. 2021 Omnibus Incentive Compensation Plan (filed as Exhibit 10.3 to Ashland’s Form 8-K filed on August 6, 2021 (SEC File No. 333-211719) and incorporated herein by reference).

 

 

 

10.47

Form of Stock Settled Performance Unit Agreement for U.S. Employees under the Ashland Global Holdings Inc. 2021 Omnibus Incentive Compensation Plan (filed as Exhibit 10.4 to Ashland’s Form 8-K filed on August 6, 2021 (SEC File No. 333-211719) and incorporated herein by reference).

 

 

 

10.48

Form of Restricted Stock Unit Agreement for U.S. Employees under the Ashland Global Holdings Inc. 2021 Omnibus Incentive Compensation Plan (filed as Exhibit 10.5 to Ashland’s Form 8-K filed on August 6, 2021 (SEC File No. 333-211719) and incorporated herein by reference).

 

 

 

10.49

Form of Stock-Settled Performance Unit Agreement for (Germany) under the Ashland Global Holdings Inc. 2021 Omnibus Incentive Compensation Plan (filed as Exhibit 10.6 to Ashland’s Form 8-K filed on August 6, 2021 (SEC File No. 333-211719) and incorporated herein by reference).

 

 

 

35


 

10.50

Form of Restricted Stock Unit Agreement for (Germany) under the Ashland Global Holdings Inc. 2021 Omnibus Incentive Compensation Plan (filed as Exhibit 10.7 to Ashland’s Form 8-K filed on August 6, 2021 (SEC File No. 333-211719) and incorporated herein by reference).

 

 

 

10.51

Form of Chief Executive Officer Change in Control Agreement (filed as Exhibit 10.69 to Ashland's Form 10-K for the fiscal year ended September 30, 2021, filed on November 22, 2021 (SEC File No. 333-211719), and incorporated by reference herein.

 

 

 

10.52

Ashland Inc. Senior Leadership Severance Plan (effective as of September 19, 2022) filed as Exhibit 10.60 to Ashland's Form 10-K for the fiscal year ended September 30, 2022, filed on November 21, 2022 (SEC File No. 333-211719), and incorporated by reference herein.

 

 

 

10.53

Form of Stock-Settled Performance Unit Agreement for US Employees, effective as of September 19, 2022 under the Ashland Global Holdings Inc. 2021 Omnibus Incentive Compensation Plan filed as Exhibit 10.61 to Ashland's Form 10-K for the fiscal year ended September 30, 2022, filed on November 21, 2022 (SEC File No. 333-211719), and incorporated by reference herein.

 

 

 

10.54

Form of Cash-Settled Performance Unit (PSU) Award Agreement for Non-US Participants, effective as of September 19, 2022 under the Ashland Global Holdings Inc. 2021 Omnibus Incentive Compensation Plan filed as Exhibit 10.62 to Ashland's Form 10-K for the fiscal year ended September 30, 2022, filed on November 21, 2022 (SEC File No. 333-211719), and incorporated by reference herein.

 

 

 

10.55

Form of Restricted Stock Unit (RSU) Award Agreement for US Participants, effective as of September 19, 2022 under the Ashland Global Holdings Inc. 2021 Omnibus Incentive Compensation Plan filed as Exhibit 10.63 to Ashland's Form 10-K for the fiscal year ended September 30, 2022, filed on November 21, 2022 (SEC File No. 333-211719), and incorporated by reference herein.

 

 

 

10.56

Form of Cash-Settled Restricted Equivalent (RSE) Award Agreement for Non-US Participants, effective as of September 19, 2022 under the Ashland Global Holdings Inc. 2021 Omnibus Incentive Compensation Plan filed as Exhibit 10.64 to Ashland's Form 10-K for the fiscal year ended September 30, 2022, filed on November 21, 2022 (SEC File No. 333-211719), and incorporated by reference herein.

 

 

 

10.57

 

Amendment No. 1 effective as of November 17, 2022, to the Ashland Global Holdings Inc. Deferred Compensation Plan for Non-Employee Directors (Amended and Restated as of May 2019) filed as Exhibit 10.65 to Ashland's Form 10-K for the fiscal year ended September 30, 2022, filed on November 21, 2022 (SEC File No. 333-211719), and incorporated by reference herein.

 

 

 

10.58

 

Ashland Inc. Independent Director Deferred Compensation Program effective as of November 17, 2022 filed as Exhibit 10.66 to Ashland's Form 10-K for the fiscal year ended September 30, 2022, filed on November 21, 2022 (SEC File No. 333-211719), and incorporated by reference herein.

 

 

 

10.59

 

Form of Restricted Stock Unit Agreement (Independent Directors), effective as of November 17, 2022 filed as Exhibit 10.67 to Ashland's Form 10-K for the fiscal year ended September 30, 2022, filed on November 21, 2022 (SEC File No. 333-211719), and incorporated by reference herein.

 

 

 

10.60

Credit Agreement dated as of January 10, 2020, among Ashland Global Holdings Inc., Ashland Chemco Inc., Ashland LLC, Ashland Services B.V., each lender from time to time party thereto, the Bank of Nova Scotia, as administrative agent, swing line lender and a letter of credit issuer, each other letter of credit issuer from time to time party thereto and Citibank, N.A., as syndication agent (filed as Exhibit 10.1 to Ashland’s Form 8-K filed on January 10, 2020 (SEC File No. 333-211719) and incorporated herein by reference).

 

 

 

 

10.61

Amended and Restated Credit Agreement dated as of July 22, 2022, among Ashland Global Holdings Inc., Ashland Chemco Inc., Ashland LLC, Ashland Services B.V., each lender from time to time party thereto, the Bank of Nova Scotia, Houston Branch, as administrative agent, swing line lender and a letter of credit issuer, each other letter of credit issuer from time to time party thereto and Citibank, N.A., as syndication agent (filed as Exhibit 10.1 to Ashland’s Form 8-K filed on July 22, 2022 (SEC File No. 333-211719) and incorporated herein by reference).

 

 

 

36


 

10.62

Second Amended and Restated Purchase and Sale Agreement, dated March 17, 2021, by and among Ashland LLC and Ashland Specialty Ingredients G.P., as originators, Ashland LLC, as initial servicer, and CVG Capital III LLC, as purchaser (filed as Exhibit 10.1 to Ashland’s Form 8-K filed on March 18, 2021 (SEC File No. 333-211719) and incorporated herein by reference).

 

 

 

10.63

Receivables Purchasing Agreement, dated March 17, 2021, by and among CVG Capital III LLC, PNC Bank, National Association, as administrative agent, PNC Bank Capital Markets LLC, as structuring agent, Ashland LLC, as initial servicer, and certain other persons from time to time party thereto (filed as Exhibit 10.2 to Ashland’s Form 8-K filed on March 18, 2021 (SEC File No. 333-211719) and incorporated herein by reference).

 

 

 

10.64